N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative disorders

JP7595593B2Active Publication Date: 2024-12-06STEP PHARMA SAS
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2021571989
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-09-20
Filing Date
2020-06-04
Publication Date
2024-12-06
Estimated Expiration
2040-06-04

Smart Images

  • Figure 0007595593000001
    Figure 0007595593000001
  • Figure 0007595593000002
    Figure 0007595593000002
  • Figure 0007595593000003
    Figure 0007595593000003
Patent Text Reader

Abstract

Compounds of formula (I) as human cytidine triphosphate synthase 1 (CTPS1) inhibitors for the treatment of proliferative disorders, such as cancer, including leukemia and lymphoma, inflammatory skin diseases, including psoriasis, or multiple sclerosis. The synthesis and characterization of exemplary compounds and their pharmaceutical data are disclosed herein (e.g., pages 64-80; Examples; Biological Examples 1 and 2; e.g., compounds P140, P231-P263; Tables 1-10). Specific examples are, for example: N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxamide (formula (II)), or 1-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)cyclohexane-1-carboxamide (formula (III)). [Formula 1] TIFF2022536092000202.tif62170
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to novel compounds, processes for the preparation of such compounds, related intermediates, compositions containing such compounds, and the use of such compounds as cytidine triphosphate synthase 1 inhibitors, particularly in the treatment or prevention of disorders associated with cell proliferation. [Background technology]

[0002] Nucleotides are important building blocks for cellular metabolic processes such as deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) synthesis. There are two types of nucleotides, which contain either purine or pyrimidine bases, both of which are important for metabolic processes. Based on this, many therapeutics have been developed that target different aspects of nucleotide synthesis, some of which inhibit the production of purine nucleotides, some of which inhibit the production of pyrimidine nucleotides or both.

[0003] Cytidine 5'-triphosphate (CTP), a pyrimidine nucleotide, is a necessary precursor for the anabolism of DNA and RNA as well as for the sialylation of phospholipids and proteins. CTP originates from two sources: a salvage pathway and a de novo synthesis pathway that relies on two enzymes, CTP synthase (or synthetase) 1 and 2 (CTPS1 and CTPS2) (Evans and Guy 2004; Higgins, et al. 2007; Ostrander, et al. 1998).

[0004] CTPS1 and CTPS2 bind uridine triphosphate (UTP) and Glutamine 、 Cytidine triphosphate (CTP) and L-glutamic acid It catalyzes the conversion of [ka]

[0005] Both enzymes have two domains: an N-terminal synthetase domain and a C-terminal glutaminase domain (Kursula, et al. 2006). The synthetase domain transfers phosphate from adenosine triphosphate (ATP) to the 4-position of UTP, resulting in the activated intermediate 4-phospho-UTP. The glutaminase domain generates ammonia from glutamine via a covalent thioester intermediate with a conserved active site cysteine, generating glutamate. This ammonium can be transferred from the glutaminase domain to the synthetase domain through a tunnel or derived from external ammonium. This ammonium is then used by the synthetase domain to generate CTP from 4-phospho-UTP (Lieberman, 1956).

[0006] CTPS exists as two isozymes, CTPS1 and CTPS2, in humans and other eukaryotes, but the functional differences between the two isozymes have not yet been fully elucidated (van Kuilenburg, et al. 2000).

[0007] The immune system has evolved to protect against infection and therefore to respond rapidly to the wide variety of pathogens to which a given individual may be exposed. This response can take many forms, but the expansion and differentiation of immune populations is a key element and is therefore closely linked to rapid cell proliferation. Within this, CTP synthase activity appears to play an important role in DNA synthesis and the rapid expansion following lymphocyte activation (Fairbanks, et al. 1995;van den Berg, et al. 1995).

[0008] Firm clinical confirmation that CTPS1 is a key enzyme in human lymphocyte proliferation came with the identification of a homozygous loss-of-function mutation (rs145092287) in this enzyme that causes a distinctive and life-threatening immunodeficiency characterized by an impaired ability of activated T and B cells to proliferate in response to antigen receptor-mediated activation. Cells lacking activated CTPS1 were found to have reduced levels of CTP. Normal T cell proliferation was restored in CTPS1-deficient cells by expressing wild-type CTPS1 or by adding cytidine. CTPS1 expression was found to be low in resting lymphocytes, but was rapidly upregulated after activation of these cells. CTPS1 expression in other tissues was generally low. CTPS2 appears to be ubiquitously expressed in various cells and tissues, but at low levels, and the inability of intact CTPS2 in patients to recruit mutated CTPS1 supports CTPS1 as a key enzyme for the affected immune population in patients (Martin, et al. 2014).

[0009] Overall, these findings suggest that CTPS1 is a key enzyme required to meet the demand for the supply of CTP required by several important immune cell populations.

[0010] Normally, the immune response is tightly regulated to ensure protection from infection while controlling any responses that target host tissues. In some situations, control of this process is ineffective, leading to immune-mediated pathology. A wide range of human diseases are believed to result from such inappropriate responses mediated by various components of the immune system.

[0011] Given the role that cell populations such as T and B lymphocytes are believed to play in a wide range of autoimmune and other diseases, CTPS1 represents a target for a new class of immunosuppressive drugs. Thus, inhibition of CTPS1 offers a new approach to the inhibition of activated lymphocytes and selected other immune cell populations such as natural killer cells, mucosal-associated invariant T (MAIT) cells, and invariant natural killer T cells, which are accentuated by the phenotype of human mutant patients (Martin, et al. 2014).

[0012] Cancer affects many cell types and tissues, but the underlying cause is a breakdown in the control of cell division. This process is highly complex, requiring the careful coordination of multiple pathways, many of which have not yet been fully characterized. Cell division requires the efficient replication of the cell's DNA and other components. Interfering with the cell's ability to replicate by targeting nucleic acid synthesis has been a central approach in cancer treatment for many years. Examples of therapeutic agents that act in this way are 6-thioguanine, 6-mercaptopurine, 5-fluorouracil, cytarabine, gemcitabine, and pemetrexed.

[0013] As indicated above, pathways involved in providing key building blocks for nucleic acid replication are the purine and pyrimidine synthesis pathways, and pyrimidine biosynthesis has been observed to be upregulated in tumor and neoplastic cells.

[0014] CTPS activity is upregulated in many tumor types of both hematological and non-hematological origin, although heterogeneity is observed between patients. High enzyme levels have also been linked to resistance to chemotherapeutic agents.

[0015] At present, the precise roles that CTPS1 and CTPS2 play in cancer are not fully understood. Several nonselective CTPS inhibitors have been developed into phase I / II clinical trials for oncology indications but have been discontinued due to toxicity and efficacy issues.

[0016] Most of the inhibitors in the above development stages are nucleoside analogue prodrugs (3-deazauridine, CPEC, carbozine), which are converted to active triphosphorylated metabolites by kinases involved in pyrimidine biosynthesis, namely uridine / cytidine kinase, nucleoside monophosphate-kinase (NMP-kinase), and nucleoside diphosphate kinase (NDP-kinase). The remaining inhibitor (acividine, DON) is a reactive analogue of glutamine that irreversibly inhibits the glutaminase domain of CTPS. Gemcitabine has also been reported to have some inhibitory activity against CTPS (McClusky et al., 2016).

[0017] Therefore, CTPS appears to be an important target in the cancer field. The properties of all the above compounds are such that their effects on other pathways likely contribute to the efficacy of these compounds in inhibiting tumors.

[0018] Therefore, selective CTPS inhibitors offer an alternative and attractive approach to tumor treatment. Compounds with different potencies against CTPS1 and CTPS2 may offer important opportunities to target different tumors depending on their relative dependence on these enzymes.

[0019] CTPS1 has also been suggested to play a role in vascular smooth muscle proliferation following vascular injury or surgery (Tang, et al. 2013).

[0020] As far as is known to date, no selective CTPS1 inhibitors have been developed. Recently, a CTPS1 selective inhibitory peptide, CTpep-3, has been identified. However, the inhibitory effect of CTpep-3 was seen in cell-free assays, not in a cellular context. However, this is not unexpected, as the peptide is unlikely to have entered the cells and therefore is not readily developable as a therapeutic agent (Sakamoto, et al. 2017).

[0021] In summary, the available information and data strongly suggest that inhibitors of CTPS1, with potential effects on other selected cell types such as vascular smooth muscle cells, would reduce the proliferation of many immune and cancer cell populations, and thus, it can be expected that inhibitors of CTPS1 will be useful in the treatment or prevention of a wide range of indications in which pathology is caused by these populations.

[0022] CTPS1 inhibitors provide a new approach to inhibit selected components of the immune system in various tissues and generally associated pathologies or pathological conditions such as rejection of transplanted cells and tissues, graft-associated diseases or disorders, allergies, and autoimmune diseases, etc. Additionally, CTPS1 inhibitors offer therapeutic potential in various cancer indications and in improving recovery from vascular injury or vascular surgery in subjects, and reducing morbidity and mortality associated with neointima and restenosis.

[0023] International patent applications WO2019 / 106156, WO2019 / 106146, WO2019 / 179652, WO2019 / 180244, and WO2020 / 083975 disclose CTPS1 inhibitors. Summary of the Invention

[0024] The present invention relates to a compound of formula (I): [ka] A compound of the formula: During the ceremony, (a) A, V, W, X, Y, Z, R 1 , R 10 , and R 12 But below: [ka] If the above is true, then R 4 and R 5 is R 4 and R 5 together with the carbon atom to which it is attached, [ka] or (b) A, V, W, X, Y, Z, R 1 , R 10 , and R 12 But below: [ka] If the above is true, then R 4 and R 5 is R 4 and R 5 along with the carbon atom to which it is attached [ka] or (c) A, V, W, X, Y, Z, R 4 , R 5 , R 10 , and R 12 But below: [ka] If the above is true, then R 1 teeth, [ka] or (d) A, V, W, X, Y, Z, R 4 , R 5 , R 10 , and R 12 But below: [ka] If the above is true, then R 1 teeth, [ka] or (e) A, X, Y, Z, R 1 , R 4 , and R 5 But below: [ka] If V, W, R 10 , and R 12 teeth, [ka] or (f) A, V, W, R 1 , R 4 , R 5 , R 10 , and R 12 But below: [ka] Then Z, X, and Y are [ka] or (g) A, V, W, R 1 , R 4 , R 5 , R 10 , and R 12 But below: [ka] Then Z, X, and Y are [ka] or (h) A, V, W, R 1 , R 4 , R 5 , R 10 , and R 12 But below: [ka] Then Z, X, and Y are [ka] That is, The above compound is provided.

[0025] The present invention also provides Formula (I): [ka] A compound of the formula: During the ceremony, (a) A, V, W, X, Y, Z, R 1 , R 10 , and R 12 But below: [ka] If the above is true, then R 4 and R 5 is R 4 and R 5 together with the carbon atom to which it is attached, [ka] or (b) A, V, W, X, Y, Z, R 1 , R 10 , and R 12 But below: [ka] If the above is true, then R 4 and R 5 is R 4 and R 5 along with the carbon atom to which it is attached [ka] or (c) A, V, W, X, Y, Z, R 4 , R 5 , R 10 , and R 12 But below: [ka] If the above is true, then R 1 teeth, [ka] or (d) A, V, W, X, Y, Z, R 4 , R 5 , R 10 , and R 12 But below: [ka] If the above is true, then R 1 teeth, [ka] or (e) A, X, Y, Z, R 1 , R 4 , and R 5 But below: [ka] If V, W, R 10 , and R 12 teeth, [ka] or (f) A, V, W, R 1 , R 4 , R 5 , R 10 , and R 12 But below: [ka] Then Z, X, and Y are [ka] or (g) A, V, W, R 1 , R 4 , R 5 , R 10 , and R 12 But below: [ka] Then Z, X, and Y are [ka] That is, The above compound is also provided.

[0026] The compound of formula (I) may be provided in the form of its salt and / or solvate and / or its derivative. Preferably, the compound may be provided in the form of its pharmaceutically acceptable salt and / or solvate and / or its derivative. In particular, the compound of formula (I) may be provided in the form of a pharmaceutically acceptable salt and / or solvate, such as a pharmaceutically acceptable salt.

[0027] Also provided is a compound of formula (I), or a pharma- ceutically acceptable salt and / or solvate thereof and / or derivative thereof, for use as a medicament, particularly for use in the prophylaxis or treatment of associated diseases or disorders, such as diseases or disorders in which inhibition of CTPS1 or reduction in T cell and / or B cell proliferation in a subject would be beneficial.

[0028] Further provided are methods for inhibiting CTPS1 in a subject or preventing or treating an associated disease or disorder, such as a disease or disorder that would benefit from reduced proliferation of T cells and / or B cells, by administering to a subject in need thereof a compound of formula (I) or a pharma- ceutically acceptable salt and / or solvate and / or derivative thereof.

[0029] Further provided is the use of a compound of formula (I), or a pharma- ceutically acceptable salt and / or solvate thereof and / or derivative thereof, in the manufacture of a medicament for the prophylaxis or treatment of a related disease or disorder, such as a disease or disorder in which inhibition of CTPS1 or reduction in T cell and / or B cell proliferation in a subject would be beneficial.

[0030] The disease or disorder is preferably selected from inflammatory skin diseases such as psoriasis or lichen planus, acute and / or chronic GVHD such as steroid-resistant acute GVHD, acute lymphoproliferative syndrome (ALPS), systemic lupus erythematosus, lupus nephritis, or cutaneous lupus, and transplantation. Additionally, the disease or disorder may be selected from myasthenia gravis, multiple sclerosis, and scleroderma / systemic sclerosis.

[0031] There is also provided a compound of formula (I), or a pharma- ceutically acceptable salt and / or solvate and / or derivative thereof, for use in the treatment of cancer.

[0032] Further provided is a method of treating cancer in a subject by administering to a subject in need thereof a compound of formula (I) or a pharma- ceutically acceptable salt and / or solvate and / or derivative thereof.

[0033] Further provided is the use of a compound of formula (I), or a pharma- ceutically acceptable salt and / or solvate and / or derivative thereof, in the manufacture of a medicament for the treatment of cancer in a subject.

[0034] There is also provided a compound of formula (I), or a pharma- ceutically acceptable salt and / or solvate and / or derivative thereof, for use in improving recovery from vascular injury or vascular surgery in a subject, and reducing morbidity and mortality associated with neointima and restenosis.

[0035] Further provided are methods of improving recovery from vascular injury or vascular surgery in a subject, and reducing morbidity and mortality associated with neointima and restenosis, by administering to a subject in need thereof a compound of formula (I) or a pharma-ceutically acceptable salt and / or solvate and / or derivative thereof.

[0036] Further provided is the use of a compound of formula (I), or a pharma- ceutically acceptable salt and / or solvate thereof and / or derivative thereof, in the manufacture of a medicament for improving recovery from vascular injury or vascular surgery in a subject, and reducing morbidity and mortality associated with neointima and restenosis.

[0037] There is also provided a pharmaceutical composition comprising a compound of formula (I), or a pharma- ceutically acceptable salt and / or solvate and / or derivative thereof, and a pharma- ceutically acceptable carrier or excipient.

[0038] Also provided are processes for the preparation of compounds of formula (I) and novel intermediates useful in the preparation of compounds of formula (I). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0039] The present invention provides a compound of formula (I) above, or a pharma- ceutically acceptable salt or solvate thereof.

[0040] The present invention also relates to a compound of formula (I): [ka] A compound of the formula: During the ceremony, (a) A, V, W, X, Y, Z, R 1 , R 10 , and R 12 But below: [ka] If the above is true, then R 4 and R 5 is R 4 and R 5 together with the carbon atom to which it is attached, [ka] or (b) A, V, W, X, Y, Z, R 1 , R 10 , and R 12 But below: [ka] If the above is true, then R 4 and R 5 is R 4 and R 5 along with the carbon atom to which it is attached [ka] or (c) A, V, W, X, Y, Z, R 4 , R 5 , R 10 , and R 12 But below: [ka] If the above is true, then R 1 teeth, [ka] or (d) A, V, W, X, Y, Z, R 4 , R 5 , R 10 , and R 12 But below: [ka] If the above is true, then R 1 teeth, [ka] or (e) A, X, Y, Z, R 1 , R 4 , and R 5 But below: [ka] If V, W, R 10 , and R 12 teeth, [ka] or (f) A, V, W, R 1 , R 4 , R 5 , R 10 , and R 12 But below: [ka] Then Z, X, and Y are [ka] or (g) A, V, W, R 1 , R 4 , R 5 , R 10 , and R 12 But below: [ka] Then Z, X, and Y are [ka] is Also provided is the above compound, or a pharma- ceutically acceptable salt and / or solvate thereof.

[0041] The present invention provides the following compounds: N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxamide, 1-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)cyclohexane-1-carboxamide, N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-1-(2-(methylsulfonamido)pyrimidin-4-yl)cyclohexane-1-carboxamide, 1-(6-(cyclopropanesulfonamido)pyrazin-2-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)cyclohexane-1-carboxamide, 4-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)-N-(4-(6-ethoxypyrazin-2-yl)-2-methylphenyl)tetrahydro-2H-pyran-4-carboxamide, 1-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)cyclobutane-1-carboxamide, 4-(4-(cyclopropanesulfonamido)pyrimidin-2-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)tetrahydro-2H-pyran-4-carboxamide, 4-(2-(cyclopentanesulfonamido)pyrimidin-4-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)tetrahydro-2H-pyran-4-carboxamide, N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-((1-methylcyclopropane)-1-sulfonamido)pyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxamide, 4-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-1-methylpiperidine-4-carboxamide, 4-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-1-isopropylpiperidine-4-carboxamide, 4-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)-N4-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-N1-isopropylpiperidine-1,4-dicarboxamide, 4-(2-((1,1-dimethylethyl)sulfonamido)pyrimidin-4-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)tetrahydro-2H-pyran-4-carboxamide, N-(4-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)tetrahydro-2H-pyran-4-yl)-5-(6-ethoxypyrazin-2-yl)picolinamide, 1-acetyl-4-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)piperidine-4-carboxamide, N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-((2-methylpropyl)sulfonamido)pyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxamide, 4-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)-N-(5-(6-cyclopropylpyrazin-2-yl)pyridin-2-yl)tetrahydro-2H-pyran-4-carboxamide, N-(5'-chloro-[3,3'-bipyridin]-6-yl)-4-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxamide, N-(1-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)cyclopropyl)-5-(6-ethoxypyrazin-2-yl)picolinamide, 4-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)tetrahydro-2H-thiopyran-4-carboxamide 1,1-dioxide, N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(ethylsulfonamido)pyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxamide, and 4-(2-(cyclopropylmethylsulfonamido)pyrimidin-4-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)tetrahydro-2H-pyran-4-carboxamide.

[0042] The present invention relates to the compound: Also provided is 4-(4-(cyclopropanesulfonamido)pyrimidin-2-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-1-methylpiperidine-4-carboxamide.

[0043] The compounds of the present invention may be provided in the form of a pharma- ceutically acceptable salt and / or solvate thereof and / or a derivative thereof.In particular, the compounds of formula (I) may be provided in the form of a pharma- ceutically acceptable salt and / or solvate thereof, such as a pharma- ceutically acceptable salt.

[0044] Particularly interesting compounds of the invention have an IC for CTPS1 of 1 uM or less, particularly 100 nM or less, using the method of the Examples (or an equivalent method). 50 It is a compound having the following formula:

[0045] Compounds of the invention of particular interest are those that exhibit 2-30 fold, preferably greater than 30-fold up to 60-fold, or more preferably greater than 60-fold selectivity for CTPS1 compared to CTPS2 using the method of the Examples (or an equivalent method). Desirably, the selectivity is for human CTPS1 relative to human CTPS2.

[0046] It will be understood that for use in medicine, the salts of the compounds of formula (I) must be pharma- ceutically acceptable. In other contexts, such as in the preparation of the compounds of formula (I), non-pharmaceutically acceptable salts of the compounds of formula (I) may be useful. Suitable pharma- ceutically acceptable salts will be apparent to those skilled in the art. Pharmaceutically acceptable salts include those described by Berge et al. (1977). Such pharma- ceutically acceptable salts include acid addition salts and base addition salts. Pharmaceutically acceptable acid addition salts can be formed with inorganic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, or phosphoric acid, and organic acids, such as succinic acid, maleic acid, acetic acid, fumaric acid, citric acid, tartaric acid, benzoic acid, p-toluenesulfonic acid, methanesulfonic acid, or naphthalenesulfonic acid. Other salts, such as oxalates or formates, may be used, for example, in the isolation of the compounds of formula (I), and are therefore also within the scope of the present invention.

[0047] Some of the compounds of formula (I) may form acid or base addition salts with equivalent amounts of the acid or base. The present invention includes within its scope all stoichiometric and non-stoichiometric forms.

[0048] The compounds of formula (I) may be prepared in crystalline or amorphous form and, if crystalline, may optionally be solvated, for example as hydrates. The present invention includes within its scope stoichiometric solvates (e.g. hydrates) as well as compounds containing variable amounts of solvent (e.g. water).

[0049] It will be understood that the present invention encompasses pharma- ceutically acceptable derivatives of the compounds of formula (I) and that these derivatives are included within the scope of the present invention.

[0050] As used herein, "pharmaceutically acceptable derivative" includes any pharmaceutically acceptable prodrug, such as an ester of a compound of formula (I) or a salt of such an ester, which, when administered to a recipient, yields (directly or indirectly) a compound of formula (I) or an active metabolite or residue thereof.

[0051] The present invention includes all isomers of formula (I) and their pharma- ceutically acceptable derivatives, including all geometric, tautomeric, and optical isomeric forms, as well as mixtures thereof (e.g., racemic mixtures). If further chiral centers are present in compounds of formula (I), the present invention includes within its scope all possible diastereomers, including mixtures thereof. The different isomeric forms may be separated or resolved one from the other by conventional methods, or any given isomer may be obtained by conventional synthetic methods or by stereospecific or asymmetric syntheses.

[0052] The present disclosure encompasses all isotopic forms of the compounds of the present invention, whether (i) all atoms of a given atomic number have a mass number (or mixture of mass numbers) that is predominant in nature (referred to herein as "natural isotopic forms"), or (ii) one or more atoms have the same atomic number but a mass number that is different from the mass number of the predominant atom in nature (referred to herein as "unnatural different isotopic forms"). It should be understood that atoms may naturally exist as a mixture of mass numbers. The term "unnatural different isotopic forms" also encompasses embodiments in which the proportion of atoms of a given atomic number that have mass numbers that are not commonly found in nature (referred to herein as "uncommon isotopes") is increased by more than 20%, more than 50%, more than 75%, more than 90%, more than 95%, or more than 99 in the number of atoms of that atomic number compared to the proportion that occurs in nature (the latter embodiment is referred to as "isotopically enriched different forms"). The term "non-natural isotopic variant" also encompasses embodiments in which the proportion of an uncommon isotope is reduced compared to the proportion occurring in nature. Isotopic forms may include radioactive forms (i.e., the form has a radioactive isotope incorporated therein) and non-radioactive forms. Radioactive forms will usually be isotopically enriched variants.

[0053] Therefore, non-naturally occurring different isotopic forms of a compound may contain deuterium ( 2 H or D), carbon 11 (11 C), carbon-13( 13 C), carbon-14( 14 C), nitrogen 13( 13 N), Nitrogen-15( 15 N), oxygen 15( 15 O), oxygen 17( 17 O), oxygen 18( 18 O), phosphorus 32 ( 32 P), sulfur 35( 35 S), Chlorine 36 ( 36 Cl), Chlorine 37( 37 Cl), Fluorine 18 ( 18 F), Iodine-123( 123 I), Iodine-125( 125 I), or may contain an increased proportion of the above isotopes at one or more atoms relative to the proportion predominant in nature.

[0054] Non-natural different isotopic forms containing radioactive isotopes may be used, for example, in drug and / or substrate tissue distribution studies. The radioactive isotope tritium, i.e. 3 H, and carbon 14, i.e. 14 C are particularly useful for this purpose due to their ease of incorporation and rapid detection. 2 Unnatural different isotopic forms incorporating H or D may confer certain therapeutic advantages due to greater metabolic stability, e.g., increased in vivo half-life or reduced dosage requirements, and therefore may be preferred in some cases. 11 C. 18 F, 15 O, and 13 Non-natural isotopic forms can also be prepared incorporating positron emitting isotopes, such as N, which would be useful in positron emission tomography (PET) studies to examine substrate receptor occupancy.

[0055] In one embodiment, the compounds of the invention are provided in natural isotopic form.

[0056] In one embodiment, the compounds of the invention are provided in non-naturally isotopic forms. In certain embodiments, the non-naturally isotopic forms include deuterium (i.e. 2 In one embodiment, the atoms of the compounds of the invention are in isotopic form that is not radioactive. In one embodiment, one or more atoms of the compounds of the invention are in isotopic form that is radioactive. The radioisotope is preferably a stable isotope. The non-natural different isotopic form is preferably a pharma- ceutically acceptable form.

[0057] In one embodiment, compounds of the invention are provided in which a single atom of the compound exists in a different, non-natural isotopic form. In another embodiment, compounds of the invention are provided in which two or more atoms exist in a different, non-natural isotopic form.

[0058] The non-natural isotopic forms can generally be prepared by conventional techniques known to those skilled in the art or by methods similar to those described herein, for example, those described in the accompanying examples, for preparing the natural isotopic forms. Thus, the non-natural isotopic forms can be prepared by substituting appropriate isotopically different (or labeled) reactants for the conventional reactants used in the examples. Since the compounds of formula (I) are intended for use in pharmaceutical compositions, it is readily understood that each of the compounds is preferably provided in substantially pure form, for example at least 60% pure, more preferably at least 75% pure, preferably at least 85% pure, and especially at least 98% pure (% being weight by weight). Less pure preparations of the compounds may be used to prepare the more pure forms used in the pharmaceutical compositions.

[0059] In general, compounds of formula (I) can be prepared by organic synthesis techniques known to those skilled in the art, as well as by the representative methods described below, the methods in the Examples, and modifications thereof.

[0060] General Pathway Outlined below are general routes by which examples of compounds of the invention may be conveniently prepared. [ka]

[0061] Generally, and as shown in Scheme 1, compounds of general formula (I) can be obtained from compounds of general formula (VIII) by a five-step process. For example, compounds P236, P237, P238, P239, P240, P252, and P253 can be prepared using the methods disclosed in this route. First, compound (VIII) can be reacted with an asymmetric malonate ester as shown in Scheme 1. For example, the asymmetric malonate ester can be reacted with Cs in the presence of (VIII) in a solvent such as DMF. 2 CO 3 and heating to an elevated temperature such as 80° C., followed by aqueous work-up, gives the compound of formula (VII). This intermediate compound is then deprotected at this stage by decarboxylation initiated by the use of a strong acid such as TFA to give the intermediate derivative (IX). Certain intermediates such as (IX) where Z=CH are commercially available. Reaction of the compound of general formula (IX) with an inorganic base such as potassium carbonate in the presence of an alkylating agent results in alkylation at the alpha position to the ester. R 4 and R 5 are combined to form C 6 In the case of compounds of formula (I) that form a cycloalkyl ring, such compounds can be prepared by double alkylation with a dihaloalkane, such as 1,2-dibromoethane or 1,3-dibromobutane, in the presence of an inorganic base, such as sodium hydroxide. 4 and R 5 But R 4 and R5 C together with the carbon to which it is bonded 6 For compounds of formula (I) that form heterocycloalkyls, Cs 2 CO 3 In the presence of a base such as BrCH at high temperatures such as 60 °C, 2 CH 2 OCH 2 CH 2 Double alkylation using aryl amines such as Br) followed by direct column chromatography can be used to provide compounds of formula (X).

[0062] Palladium catalyzed sulfamination of intermediate (X) can be carried out using a catalyst such as [t-BuXPhosPd(allyl)]OTf or t-BuXPhos-Pd-G3 and a substituted sulfonamide nucleophile (VI) in the presence of an inorganic base such as potassium carbonate to form intermediate derivative (II). Alternatively, sulfamination of intermediate (X) can be carried out in the presence of an inorganic base such as Cs 2 CO 3 and N-methylpyrrolidone to form the intermediate derivative (II), which can be obtained by precipitation after dilution in 4M aqueous HCl.

[0063] The final compound of general formula (I) can be prepared by conversion of intermediate (II) by activation of the ester moiety with trimethylaluminum (usually 2.0 M in toluene or heptane) and addition of amine (III) (commercially available or prepared as in Scheme 2 below). Alternatively, compounds of formula (I) can be obtained by strong base-mediated amide formation between compounds (II) and (III) at room temperature using bases such as iPrMgCl, LiHMDS, or KOtBu. [ka]

[0064] W, V, R10 , and R 12 Intermediates of formula (III), as defined above, can be synthesized by coupling of boronic acids (esters) of general formula (XII), where Z represents a dihydroxyboryl or dialkyloxyboryl group, usually 4,4,5,5-tetramethyl-1,3,3,2-dioxaborolan-2-yl group, with compounds of formula (XI), where X represents a halide, under Suzuki conditions. Alternatively, X represents a dihydroxyboryl or dialkyloxyboryl group, usually 4,4,5,5-tetramethyl-1,3,3,2-dioxaborolan-2-yl group, and Z represents a halide. Coupling according to the Suzuki method can be carried out, for example, by heating in a solvent mixture of dioxane and water, in the presence of a catalyst such as [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane, and an inorganic base such as potassium carbonate.

[0065] [ka] R is H, C 1~4 alkyl (e.g., methyl and ethyl), or benzyl. Generally, and as shown in Scheme 3a, R 1 , X, Y, Z, V, W, R 10 , and R 12 is as defined above, and for example, R 4 and R 5 But R 4 and R 5 C together with the carbon atom to which it is attached 3~6 Heterocycloalkyl ring or C 4Compounds of formula (I) forming a cycloalkyl ring can be prepared in four steps from compounds of formula (LVX). For example, compounds P241, P243, and P259 can be prepared using this route. Intermediates of formula (XXXVII) can be coupled with compounds of formula (LVX) in the presence of a base such as LiHMDS to give compounds of formula (XXXIII). Thioethers of general formula (XXXIII) can be converted to sulfones (XXXIV) in the presence of an oxidizing agent such as mCPBA. The sulfone group can be oxidized with Cs 2 CO 3 and a solvent such as N-methylpyrrolidone to give compounds of formula (II). Compounds of formula (I) can be obtained by strong base mediated amide formation between compounds (II) and (III) at room temperature using bases such as iPrMgCl, LiHMDS, or KOtBu.

[0066] [ka] R is H, C 1~4 alkyl (e.g., methyl and ethyl), or benzyl. Generally, and as shown in Scheme 3b, R 1 , X, Y, Z, V, W, R 10 , and R 12 is as defined above, and for example, R 4 and R 5 But R 4 and R 5 C together with the carbon atom to which it is attached 3~6Compounds of formula (I) forming a heterocycloalkyl ring can be prepared in three steps from compounds of formula (XXXIII). For example, compounds P231, P232, P233, P234, P245, P246, P247, P250, P262, and P263 can be prepared using this route. Compounds of formula (LXI) can be obtained by amide formation between compounds (XXXIII) and (III) mediated by a strong base at room temperature using a base such as iPrMgCl, LiHMDS, or KOtBu. Thioethers of general formula (LXI) can be converted to sulfoxides (n=1) or sulfones (n=2) (LXII) in the presence of an oxidizing agent such as mCPBA. The sulfoxide or sulfone group can be oxidized with Cs 2 CO 3 Substitution with a primary sulfonamide (VI) in the presence of a base such as and a solvent such as N-methylpyrrolidone provides compounds of formula (I).

[0067] [ka] R is H, C 1~4 alkyl (e.g., methyl and ethyl), or benzyl. Generally, and as shown in Scheme 3c, R 1 , X, Y, Z, V, W, R 4 , R 5 , R 10 , and R 12 Compounds of formula (I), where is as defined above, can be prepared in five steps from compounds of formula (LVX). For example, compound P319 can be prepared using this route. Intermediate of formula (XXXVII) can be coupled with compounds of formula (LVX) in the presence of a base such as LiHMDS to give compounds of formula (XXXIII). Thioethers of general formula (XXXIII) can be converted to sulfoxides (XXXIVa) in the presence of an oxidizing agent such as mCPBA. The sulfoxide group can be oxidized with Cs 2 CO 3Substitution with primary sulfonamide (VI) in the presence of a base such as and a solvent such as N-methylpyrrolidone gives compounds of formula (II). Compounds of formula (I) can be obtained by strong base mediated amide formation between compounds (II) and (III) using a base such as iPrMgCl, LiHMDS, or KOtBu at room temperature, followed by removal of the Boc group using a strong acid such as TFA and reductive amination under standard conditions.

[0068] [ka] In the formula, R is H, C 1~4 alkyl (e.g., methyl and ethyl), or benzyl. Generally, and as shown in Scheme 3d, R 1 , X, Y, Z, V, W, R 10 , and R 12 is as defined above, and for example, R 4 and R 5 But R 4 and R 5 C together with the carbon atom to which it is attached 6 Compounds of formula (I) forming a heterocycloalkyl ring can be prepared in three steps from compounds of formula (XXXXV), which are utilized by the methods shown in the Examples. For example, compounds P249 and P257 can be prepared using this route. Compounds of formula (XXXXVI) can be obtained by amide formation between compounds (XXXXIII) and (XXXXV) mediated by a strong base at room temperature using a base such as iPrMgCl, LiHMDS, or KOtBu. Thioethers of general formula (XXXXVI) can be converted to sulfoxides (n=1) or sulfones (n=2) (XXXXVII) in the presence of an oxidizing agent such as mCPBA. The sulfoxide or sulfone group can be oxidized by the addition of Cs 2 CO 3 Substitution with a primary sulfonamide (VI) in the presence of a base such as and a solvent such as N-methylpyrrolidone provides compounds of formula (I).

[0069] [ka] R 1 , V, W, R 10 , R 12 is as defined above, X is N, Y is CH, Z is CH, and R 4 and R 5 But R 4 and R 5 C together with the carbon to which it is bonded 3 Cycloalkyl or C 6 Compounds of general formula (I) forming a heterocycloalkyl ring can be obtained in a six-step process as shown in Scheme 4. For example, compounds P249 and P257 can be prepared using this route. First, derivative (IX) is reacted with an alkyl halide to give R 4 and R 5 Combined to form C 3 Compounds of general formula (X) can be obtained which form a cycloalkyl ring. Alternatively, derivatives (IX) can be converted to heteroalkyl bishalides (e.g. Br-CH 2 CH 2 OCH 2 CH 2 -Br) and R 4 and R 5 Combined together, we get the above defined C 6Compounds of general formula (X) can be obtained, which can form heterocycloalkyl rings. Carboxylic acids (XXXII) can be obtained by hydrolysis of methyl esters (X) using an alkali metal base such as lithium hydroxide in a solvent mixture such as THF / MeOH. For example, a Curtius rearrangement can be performed using diphenylphosphoryl azide in the presence of triethylamine and tert-butanol to obtain carbamates such as (XXXXIV). The corresponding sulfonamides (XXXXI) can then be accessed by palladium-catalyzed sulfamination using the conditions already described in Scheme 1. Formula (XXXXII) can then be converted to amides of general formula (I) using amide coupling conditions by using a coupling agent with biaryl carboxylic acids (XXXXIII) prepared according to Scheme 5.

[0070] [ka] W, V, R 10 , and R 12 Intermediates of formula (XXXXIII), where X is as defined above, can be synthesized by coupling of aromatic halides of general formula (XII) with boronic acids (esters) of general formula (XI), where X represents a dihydroxyboryl or dialkyloxyboryl group, such as 4,4,5,5-tetramethyl-1,3,3,2-dioxaborolan-2-yl group, under Suzuki conditions, as shown in Scheme 5. The Suzuki coupling can be carried out, for example, by reaction of [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II)·CH in a solvent mixture of dioxane and water under an inert atmosphere, such as nitrogen. 2 Cl 2 The reaction is carried out by heating in the presence of a catalyst such as an adduct and an inorganic base such as cesium carbonate to give a compound of formula (LVIX). Carboxylic acids of general formula (XXXXIII) can be prepared by the reaction of CH 2 Cl 2can be obtained either by deprotection of the t-butyl ester with a strong acid such as TFA in a solvent such as 0.1%, by hydrolysis of the methyl ester with an alkali metal hydroxide such as NaOH in a solvent mixture such as THF / MeOH, or by hydrolysis of the nitrile with a strong acid such as concentrated hydrochloric acid.

[0071] Intermediates of the Invention The present invention also relates to novel intermediates in the synthesis of compounds of formula (I), such as compounds of formula (II) to (LVIX). Intermediates of particular interest are compounds of the following general formula: ·Formula (II): [ka] wherein R is H, C 1~4 the above compounds being alkyl (e.g., methyl and ethyl), or benzyl; ·Formula (XXXIII): [ka] A compound of the formula: In the formula, R is H, C 1~4 the above compounds being alkyl (e.g., methyl and ethyl), or benzyl; ·Formula (XXXIV): [ka] A compound of the formula: In the formula, R is H, C 1~4 the above compounds being alkyl (e.g., methyl and ethyl), or benzyl; ·Formula (XXXIVa): [ka] A compound of the formula: In the formula, R is H, C 1~4 the above compounds being alkyl (e.g., methyl and ethyl), or benzyl; ·Formula (LXI): [ka] A compound of the formula: The compound (LXI), wherein all variables are as defined elsewhere herein. Formula (LXII): [ka] A compound of the formula: The compound (LXII), wherein all variables are as defined elsewhere herein. ·Formula (XXXI): [ka] A compound of the formula: (XXXI) is the above compound, wherein all variables are as defined elsewhere herein; ·Formula (XXXXII): [ka] A compound of the formula: All variables in (XXXXII) are as defined elsewhere herein. It is an intermediate of

[0072] Formula (II-a): [ka] A compound of the formula: In the formula, R is H, C 1~4 alkyl (e.g., methyl and ethyl), or benzyl, and X, Y, Z, and R1 are as defined herein; Formula (XXXIII-a): [ka] A compound of the formula: In the formula, R is H, C 1~4alkyl (e.g., methyl and ethyl), or benzyl, and X, Y, and Z are as defined above; Formula (XXXIVa-a): [ka] A compound of the formula: In the formula, R is H, C 1~4 alkyl (e.g., methyl and ethyl), or benzyl, and X, Y, and Z are as defined herein. Also provided is a compound selected from the group consisting of: or a salt, such as a pharma- ceutically acceptable salt, thereof.

[0073] Formula (IP): [ka] A compound of the formula: Also provided is the above compound, wherein P is a suitable nitrogen protecting group, such as Boc, and the remaining variables are as defined herein, or a salt, such as a pharma- ceutically acceptable salt thereof.

[0074] Formula (I-DP): [ka] A compound of the formula: Also provided is the above compound, wherein all variables are as defined herein, or a salt, such as a pharma- ceutically acceptable salt, thereof.

[0075] Intermediates INTC180 to INTC183, Intermediate INTC185, Intermediate INTC189, ·Intermediates INTC193~INTC196, ·Intermediate INTC200, ·Intermediate INTC202, ·Intermediate INTC204, ·Intermediate INTC206, ·Intermediate INTC209, ·Intermediate INTC211, ·Intermediate INTC213, ·Intermediate INTC217, ·Intermediates INTC219~INCT222, Intermediates INTC241 to INTC243, and Intermediates INTC246 and INTC247 All intermediates described in the examples, including those shown below, are included as aspects of the present invention.

[0076] Salts, such as pharma- ceutically acceptable salts, of any one of the intermediates disclosed herein, such as any one of the compounds of formulae (II)-(LXI), are included as an embodiment of the invention.

[0077] Treatment method The compounds of formula (I) of the present invention have utility as inhibitors of CTPS1.

[0078] The present invention therefore also provides a compound of formula (I) or a pharma- ceutically acceptable salt and / or solvate thereof and / or derivative thereof for use as a medicament, in particular in the treatment or prevention of diseases or disorders in which an inhibitor of CTPS1 is beneficial, such as the diseases and disorders mentioned herein below.

[0079] The present invention provides a method for the treatment or prevention of a disease or disorder in which inhibition of CTPS1 is beneficial, such as the diseases and disorders described herein below, comprising administering to a subject in need thereof an effective amount of a compound of formula (I) or a pharma- ceutically acceptable salt and / or solvate (e.g., salt) and / or derivative thereof.

[0080] The present invention also provides the use of a compound of formula (I), or a pharma- ceutically acceptable salt and / or solvate (e.g. a salt) and / or derivative thereof, in the manufacture of a medicament for the treatment or prevention of a disease or disorder in which a method of inhibiting CTPS1 is beneficial, such as the diseases and disorders described herein below.

[0081] More preferably, said disease or disorder in which an inhibitor of CTPS1 is beneficial is a disease or disorder in which a reduction in T cell and / or B cell proliferation would be beneficial.

[0082] The present invention also provides the use of a compound of formula (I), or a pharma- ceutically acceptable salt and / or solvate (eg a salt) and / or derivative thereof, for use in inhibiting CTPS1.

[0083] The present invention provides a method for inhibiting CTPS1 in a subject, the method comprising administering to the subject an effective amount of a compound of formula (I) or a pharma- ceutically acceptable salt and / or solvate (e.g., a salt) and / or derivative thereof.

[0084] The invention also provides the use of a compound of formula (I), or a pharma- ceutically acceptable salt and / or solvate (e.g. a salt) and / or derivative thereof, in the manufacture of a medicament for the inhibition of CTPS1 in a subject.

[0085] The present invention also provides a compound of formula (I), or a pharma- ceutically acceptable salt and / or solvate (e.g. a salt) and / or derivative thereof, for use in reducing the proliferation of T cells and / or B cells in a subject.

[0086] The present invention provides a method of reducing T cell and / or B cell proliferation in a subject comprising administering to the subject an effective amount of a compound of formula (I) or a pharma- ceutically acceptable salt and / or solvate (e.g. a salt) and / or derivative thereof.

[0087] The invention also provides the use of a compound of formula (I), or a pharma- ceutically acceptable salt and / or solvate (e.g. a salt) and / or derivative thereof, in the manufacture of a medicament for reducing the proliferation of T cells and / or B cells in a subject.

[0088] More preferably, said disease or disorder in which an inhibitor of CTPS1 would be beneficial is a disease or disorder in which a reduction in T cell and / or B cell proliferation would be beneficial.

[0089] The term "treatment" or "treating" as used herein includes the control, alleviation, relief, or modification of a disease state or its symptoms.

[0090] The terms "prophylaxis" or "preventing" are used herein to mean the prevention of symptoms of a disease or disorder in a subject, or the prevention of the recurrence of symptoms of a disease or disorder in an afflicted subject, and are not limited to complete prevention of the affliction.

[0091] Suitably, the disease or disorder is selected from rejection of transplanted cells and tissues, transplant-associated diseases or disorders, allergies, and autoimmune diseases.

[0092] In one embodiment, the disease or disorder is rejection of transplanted cells and tissues. The subject may have a transplanted tissue selected from the group consisting of heart, kidney, lung, liver, pancreas, pancreatic islets, brain tissue, stomach, large intestine, small intestine, diaphragm, skin, trachea, bone, bone marrow (or any other source of hematopoietic precursor and stem cells, including hematopoietic cells mobilized from bone marrow to peripheral blood or umbilical cord blood cells), muscle, or bladder. The compounds of the present invention are useful for preventing or suppressing immune responses associated with rejection of donor tissue, cell, graft, or organ transplants in subjects.

[0093] In further embodiments, the disease or disorder is a graft-related disease or disorder. Graft-related diseases or disorders include graft-versus-host disease (GVHD), such as GVHD associated with bone marrow transplantation, and immune disorders resulting from or associated with transplantation of organ, tissue, or cell transplants (e.g., tissue or cell allografts or xenografts), including, for example, skin, muscle, nerve, pancreatic islet, organ, liver parenchymal cells, and host-versus-graft disease (HVGD). Compounds of the present invention may be useful in preventing or suppressing acute rejection of such transplants in transplant recipients, and / or for long-term maintenance therapy to prevent rejection of such transplants in transplant recipients (e.g., suppressing rejection of transplants of insulin-producing pancreatic islet cells from donors in diabetic patients). Thus, compounds of the present invention are useful for preventing host-versus-graft disease (HVGD) and graft-versus-host disease (GVHD).

[0094] The CTPS1 inhibitor may be administered before, after, and / or during transplantation. In some embodiments, the CTPS1 inhibitor may be administered to the subject periodically before and / or after transplantation.

[0095] In another embodiment, the disease or disorder is an allergy.

[0096] In a further embodiment, the immune-related disease or disorder is an autoimmune disease. As used herein, an "autoimmune disease" refers to a disease or disorder that is directed against the subject's own tissue. Examples of autoimmune diseases include Addison's disease, adult-onset Still's disease, alopecia areata, Alzheimer's disease, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, ankylosing spondylitis, antiphospholipid syndrome (Hughes syndrome), aplastic anemia, arthritis, asthma, atherosclerosis, atherosclerotic plaques, atopic dermatitis, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune hypophysitis (lymphocytic hypophysitis), autoimmune inner ear disease, autoimmune lymphoproliferative syndrome, autoimmune myocarditis, autoimmune neutropenia, autoimmune oophoritis, autoimmune orchitis, immunosuppressive disorders, and immunosuppressive disorders. Autoinflammatory diseases requiring immunosuppressive therapy, azoospermia, Behçet's disease, Berger's disease, bullous pemphigoid, cardiomyopathy, cardiovascular disease, celiac disease including refractory celiac disease (types I and II), chronic fatigue immune deficiency syndrome (CFIDS), chronic idiopathic polyneuropathy, chronic inflammatory demyelinating polyneuropathy (CIPD), chronic relapsing polyneuropathy (Guillain-Barré syndrome), Churg-Strauss syndrome (CSS), cicatricial pemphigoid, cold agglutinin disease (CAD), chronic obstructive pulmonary disease (COPD), CREST syndrome, cryoglobulinemia syndrome (CROS)Syndromes), Cutaneous Lupus, Dermatitis Herpetiformis, Dermatomyositis, Eczema, Epidermolysis Bullosa Acquisita, Essential Mixed Cryoglobulinemia, Evans Syndrome, Exophthalmos, Fibromyalgia, Goodpasture's Syndrome, Graves' Disease, Hemophagocytic Lymphohistiocytosis (HLH) (including Type 1 Hemophagocytic Lymphohistiocytosis), Histiocytosis / Histiocytic Disorders, Hashimoto's Thyroiditis, Idiopathic Pulmonary Fibrosis, Idiopathic Thrombocytopenic Purpura (ITP), IgA Nephropathy, Immunoproliferative Disease or Disorder, Inflammatory Bowel Disease (IBD), Interstitial Lung Disease, Juvenile Arthritis, Juvenile Idiopathic Arthritis (JIA), Kawasaki Disease, Lambert-Eaton Myasthenic Syndrome, Lichen Planus, Localized Scleroderma, Lupus Nephritis, Meniere's Disease, Microangiopathic Hemolytic Anemia, Microscopic Polyangiitis, Miller Fisher Syndrome / Acute Disseminated Radiculopathy, Mixed Connective Tissue Disease, Multiple Sclerosis (MS), Muscular Rheumatism, Myalgic Encephalomyelitis (ME), Myasthenia Gravis, Eye Inflammation, pemphigus foliaceus, pemphigus vulgaris, pernicious anemia, polyarteritis nodosa, polychondritis, polyglandular syndrome (Whittaker's syndrome), polymyalgia rheumatica, polymyositis, primary agammaglobulinemia, primary biliary cirrhosis / autoimmune cholangitis, primary glomerulonephritis, primary sclerosing cholangitis, psoriasis, psoriatic arthritis, true erythrocytic anemia, Raynaud's phenomenon, Reiter's syndrome / reactive arthritis, relapsing polychondritis, restenosis, rheumatic fever, rheumatoid arthritis These include, but are not limited to, chronic myelopathy, rheumatoid arthritis, sarcoidosis, Schmidt's syndrome, scleroderma / systemic sclerosis, Sjogren's syndrome, stiff-body syndrome, Sweet's syndrome (febrile neutrophilic dermatosis), systemic lupus erythematosus (SLE), systemic scleroderma, Takayasu's arteritis, temporal arteritis / giant cell arteritis, thyroiditis, type 1 diabetes, type 2 diabetes, uveitis, vasculitis, vitiligo, Wegener's granulomatosis, and X-linked lymphoproliferative disorder.

[0097] Diseases or disorders not related to alloreactivity, including: *Alopecia areata, atopic dermatitis, eczema, psoriasis, lichen planus, psoriatic arthritis, vitiligo, *Uveitis, *Ankylosing spondylitis, Reiter's syndrome / reactive arthritis, *Aplastic anemia, autoimmune lymphoproliferative syndrome / disorder, hemophagocytic lymphohistiocytosis, *Type 1 diabetes, and * Refractory celiac disease Acute rejection of transplanted tissues and organs; acute graft-versus-host disease (GVHD) following transplantation of bone marrow cells or any other source of allogeneic cells, including hematopoietic precursor cells and / or stem cells Of particular interest are diseases or disorders that are primarily driven by T cell activation and proliferation, including

[0098] Diseases or disorders in which the involvement of pathogenic autoantibodies has been well characterized, including: *allergy, *Cicatricial pemphigoid, Bullous pemphigoid, Epidermolysis bullosa acquisita, Pemphigus foliaceus, Pemphigus vulgaris, Dermatitis herpetiformis, *ANCA-associated vasculitis and microscopic polyangiitis, vasculitis, Wegener's granulomatosis; Churg-Strauss syndrome (CSS), polyarteritis nodosa, cryoglobulin syndrome and essential mixed cryoglobulinemia, *Systemic lupus erythematosus (SLE), antiphospholipid syndrome (Hughes syndrome), cutaneous lupus, lupus nephritis, mixed connective tissue disease, *Thyroiditis, Hashimoto's thyroiditis, Graves' disease, exophthalmos, *Autoimmune hemolytic anemia, autoimmune neutropenia, ITP, pernicious anemia, euerythroid anemia, microangiopathic hemolytic anemia, *Primary glomerulonephritis, Berger's disease, Goodpasture's syndrome, IgA nephropathy, and *Chronic idiopathic polyneuropathy, chronic inflammatory demyelinating polyneuropathy (CIPD), chronic relapsing polyneuropathy (Guillain-Barre syndrome), Miller-Fisher syndrome, stiff-body syndrome, Lambert-Eaton myasthenic syndrome, myasthenia gravis, Diseases and disorders in which B cell involvement is less clearly characterized (although sometimes illustrated by the efficacy of intravenous infusion of anti-CD20 monoclonal antibodies or immunoglobulins) and which likely does not correspond to or is not limited to the production of pathogenic antibodies (although non-pathogenic antibodies are sometimes reported or, even more often, present and used as diagnostic biomarkers), including: *Addison's disease, autoimmune oophoritis and azoospermia, polyglandular syndrome (Whittaker syndrome), Schmidt syndrome, *Autoimmune myocarditis, cardiomyopathy, Kawasaki disease, *Rheumatoid arthritis, Sjogren's syndrome, mixed connective tissue disease, polymyositis and dermatomyositis, polychondritis, *Primary glomerulonephritis, *Multiple sclerosis, *Autoimmune hepatitis, primary biliary cirrhosis / autoimmune cholangopathy, *Hyperacute rejection of transplanted organs, *Chronic rejection of the graft or transplant, *Chronic graft-versus-host reaction / disease following transplantation of bone marrow or hematopoietic precursor cells Also of interest are diseases or disorders driven by T and B cell activation and proliferation, with significant participation of B cells, including

[0099] moreover, COPD, idiopathic pulmonary fibrosis, interstitial lung disease, sarcoidosis, Adult-onset Still's disease, juvenile idiopathic arthritis, systemic sclerosis, CREST syndrome, Sweet's syndrome, Takayasu's arteritis, temporal arteritis / giant cell arteritis, which may also involve B cells and pathogenic antibodies Ulcerative cholangitis, inflammatory bowel disease (IBD) including Crohn's disease and ulcerative colitis, primary sclerosing cholangitis Also of interest are diseases or disorders in which mechanisms are shared between activation / proliferation of T cells and activation / proliferation of subpopulations of innate immune cells and other inflammatory cells (including myeloid cells such as macrophages or granulocytes) and resident cells (such as fibroblasts and endothelial cells), including

[0100] *Alzheimer's disease, cardiovascular syndrome, type 2 diabetes, restenosis, chronic fatigue immune deficiency syndrome (CFIDS) Autoimmune lymphoproliferative disorders, including: *Autoimmune lymphoproliferative syndrome and X-linked lymphoproliferative disorder Also of interest are diseases or disorders whose mechanisms remain poorly characterized but which involve T cell activation and proliferation, including

[0101] The disease or disorder is preferably selected from inflammatory skin diseases such as psoriasis or lichen planus, acute and / or chronic GVHD such as steroid-resistant acute GVHD, acute lymphoproliferative syndrome, systemic lupus erythematosus, lupus nephritis or cutaneous lupus, or transplantation.Furthermore, the disease or disorder may be selected from myasthenia gravis, multiple sclerosis, and scleroderma / systemic sclerosis.

[0102] The compounds of formula (I) may also be used in the treatment of cancer.

[0103] Thus, in one embodiment there is provided a compound of formula (I), or a pharma- ceutically acceptable salt and / or solvate and / or derivative thereof, for use in the treatment of cancer.

[0104] Further provided is a method of treating cancer in a subject by administering to the subject a compound of formula (I) or a pharma- ceutically acceptable salt and / or solvate and / or derivative thereof.

[0105] Further provided is the use of a compound of formula (I), or a pharma- ceutically acceptable salt and / or solvate and / or derivative thereof, in the manufacture of a medicament for the treatment of cancer in a subject.

[0106] The above cancers are acute myeloid leukemia, angioimmunoblastic T-cell lymphoma, B-cell acute lymphoblastic leukemia, Sweet's syndrome, T-cell non-Hodgkin's lymphoma (including natural killer cell / T-cell lymphoma, adult T-cell leukemia / lymphoma, enteropathic T-cell lymphoma, hepatosplenic T-cell lymphoma, and cutaneous T-cell lymphoma), T-cell acute lymphoblastic leukemia, B-cell non-Hodgkin's lymphoma (including Burkitt's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, and pulmonary lymphoma), and and / or hematological cancers such as myeloid leukemia, primary myelodysplastic syndromes, primary plasma cell myeloma, primary mediastinal large B-cell lymphoma, chronic myeloproliferative disorders (chronic myelogenous leukemia, primary myelofibrosis, essential thrombocythemia, polycythemia vera, etc.), or chronic lymphocytic leukemia.

[0107] Alternatively, the cancer is a non-hematological cancer, such as a non-hematological cancer selected from the group consisting of bladder cancer, breast cancer, melanoma, neuroblastoma, malignant pleural mesothelioma, and sarcoma.

[0108] In addition, the compound of formula (I) may be used in improving recovery from vascular injury or vascular surgery in a subject, and reducing morbidity and mortality associated with neointima and restenosis. For example, the compound of formula (I) may be used to prevent, reduce, or inhibit neointima formation. To prevent, reduce, or inhibit neointima formation after a medical device or implant is inserted or implanted into a subject, the device may be treated with an effective amount of a composition comprising a compound of formula (I) before insertion or implantation. The device may be a device that is temporarily inserted into a subject, or a device that is permanently implanted. In some embodiments, the device is a surgical device. Examples of medical devices include, but are not limited to, needles, cannulas, catheters, shunts, balloons, and implants such as stents and valves.

[0109] Preferably, the subject is a mammal, and in particular, the subject is a human.

[0110] Pharmaceutical Compositions When used in therapy, the compounds of the invention are usually administered as pharmaceutical compositions. The invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharma- ceutically acceptable salt and / or solvate (e.g., salt) and / or derivative thereof, and a pharma- ceutically acceptable carrier or excipient.

[0111] In one embodiment, there is also provided a pharmaceutical composition comprising a compound of formula (I), or a pharma- ceutically acceptable salt and / or solvate (e.g., salt) and / or derivative thereof, for use in the treatment or prevention of a disease or disorder as described herein.

[0112] In a further embodiment, there is provided a method for the prevention or treatment of a disease or disorder as described herein, comprising administering to a subject in need thereof an effective amount of a compound of formula (I) or a pharma- ceutically acceptable salt and / or solvate (e.g. a salt) and / or derivative thereof.

[0113] The invention also provides the use of a pharmaceutical composition comprising a compound of formula (I), or a pharma- ceutically acceptable salt and / or solvate (e.g. a salt) and / or derivative thereof, in the manufacture of a medicament for the treatment or prevention of a disease or disorder as described herein.

[0114] The compounds of formula (I) or their pharma- ceutically acceptable salts and / or solvates and / or derivatives may be administered in any convenient manner, for example by oral, parenteral, buccal, sublingual, nasal, rectal or transdermal administration, and pharmaceutical compositions adapted accordingly.

[0115] The compounds of formula (I) or their pharma- ceutically acceptable salts and / or solvates and / or derivatives thereof may be administered topically, for example to the eye, intestine, or skin.Thus, in one embodiment, there is provided a pharmaceutical composition comprising a compound of the invention, optionally in combination with one or more topically acceptable diluents or carriers.

[0116] The pharmaceutical composition of the present invention may be delivered topically to the skin. Suitable compositions for transdermal administration include ointments, gels, and patches. Such pharmaceutical compositions may be suitably in the form of creams, lotions, foams, powders, pastes, or tinctures.

[0117] The pharmaceutical compositions may suitably include vitamin D3 (e.g., calcipotriol and maxacalcitol), steroids (e.g., fluticasone propionate, betamethasone valerate, clobetasol propionate), retinoids (e.g., tazarotene), coal tar, and dithranol. Topical medications are often used in combination with each other (e.g., vitamin D3 and steroids) or with additional agents such as salicylic acid.

[0118] The pharmaceutical compositions of the invention may be delivered locally to the eye. Such pharmaceutical compositions may suitably be in the form of eye drops or ointment.

[0119] The pharmaceutical compositions of the present invention may be delivered locally to the intestine. Such pharmaceutical compositions may suitably be delivered orally, such as in the form of a tablet or capsule, or rectally, such as in the form of a suppository.

[0120] The delayed release formulation is preferably in the form of a capsule.

[0121] The compounds of formula (I) or their pharma- ceutically acceptable salts and / or solvates and / or derivatives thereof that are active when given orally may be formulated as liquids or solids, for example as syrups, suspensions, emulsions, tablets, capsules, or lozenges.

[0122] Liquid formulations will generally consist of a suspension or solution of the active ingredient (such as a compound of formula (I) or a pharma- ceutically acceptable salt and / or solvate (e.g., salt) and / or derivative thereof) in an appropriate liquid carrier(s), for example, an aqueous solvent such as water, ethanol, or glycerin, or a non-aqueous solvent such as polyethylene glycol or an oil. The formulation may also contain a suspending agent, a preservative, a flavoring agent, and / or a coloring agent.

[0123] A composition in the form of a tablet can be formulated using any suitable carrier(s) routinely used for preparing solid formulations, such as magnesium stearate, starch, lactose, sucrose, and cellulose.

[0124] A composition in the form of a capsule may be formulated using conventional encapsulation procedures, for example by preparing pellets containing the active ingredient (such as the compound of formula (I) or pharma- ceutically acceptable salts and / or solvates (e.g. salts) and / or derivatives thereof) using standard carriers and then filling into a hard gelatin capsule, or by preparing a dispersion or suspension using any suitable pharmaceutical carrier(s), for example, aqueous gums, celluloses, silicates, or oils, and filling the dispersion or suspension into a soft gelatin capsule.

[0125] A typical parenteral composition will consist of a solution or suspension of the active ingredient (such as a compound of formula (I) or a pharma- ceutically acceptable salt and / or solvate (e.g., salt) and / or derivative thereof) in a sterile aqueous carrier or parenterally acceptable oil, such as polyethylene glycol, polyvinylpyrrolidone, lecithin, peanut oil, or sesame oil. Alternatively, the solution may be lyophilized and then reconstituted with an appropriate solvent just prior to administration.

[0126] Compositions for nasal administration can be conveniently formulated as aerosols, tablets, gels, and powders. Aerosol formulations generally contain a solution or fine suspension of the active ingredient in a pharma-ceutically acceptable aqueous or non-aqueous solvent, and are provided in single or multiple doses in a sterile form in a sealed container that can be in the form of a cartridge or refill for use with a nebulizer. Alternatively, the sealed container can be a disposable dispenser, such as a single-dose nasal inhaler or an aerosol dispenser with a metering valve. When the dosage form comprises an aerosol dispenser, it will contain a propellant, which can be a compressed gas, e.g., air, or an organic propellant, such as a fluorochlorohydrocarbon or hydrofluorocarbon. Aerosol dosage forms can also be in the form of a pump-action atomizer.

[0127] Compositions suitable for buccal or sublingual administration include tablets, lozenges, and pastilles, wherein the active ingredient is formulated with a carrier such as sugar and acacia, tragacanth, or gelatin and glycerin.

[0128] Compositions for rectal administration are conveniently in the form of suppositories containing a conventional suppository base such as cocoa butter.

[0129] The composition is suitably in unit dosage form, such as a tablet, capsule or ampoule.

[0130] The composition may contain, for example, 0.1% to 100% by weight, for example 10 to 60% by weight, of the active substance, depending on the method of administration. The composition may contain, for example, 0% to 99% by weight, for example 40 to 90% by weight, of the carrier, depending on the method of administration. The composition may contain, for example, 0.05 mg to 2000 mg, for example 1.0 mg to 500 mg, of the active substance, depending on the method of administration. The composition may contain, for example, 50 mg to 1000 mg, for example 100 mg to 400 mg, of the carrier, depending on the method of administration. The dose of the compound used in the treatment or prevention of the disorders described below will vary in the usual way with the severity of the disorder, the weight of the patient, and other similar factors. However, as a general guide, a suitable unit dose may be 0.05 mg to 500 mg, and such a unit dose may be administered more than once a day, for example two or three times a day. Such treatment may extend for weeks or months.

[0131] The present invention provides in a further aspect a combination comprising a compound of formula (I) or a pharma- ceutically acceptable salt, solvate and / or derivative thereof (e.g. a combination comprising a compound of formula (I) or a pharma- ceutically acceptable derivative thereof) with a further pharma- ceutically acceptable active ingredient or ingredients.

[0132] The present invention provides compounds of formula (I) for use in combination with a further pharma- ceutically acceptable active ingredient or ingredients.

[0133] When the compounds are used in combination with other therapeutic agents, the compounds may be administered separately, sequentially or simultaneously by any convenient route.

[0134] The optimal combination may depend on the disease or disorder in question. Possible combinations include 5-aminosalicylic acid, or a prodrug thereof (such as sulfasalazine, olsalazine, or bisalazide); a corticosteroid (e.g., prednisolone, methylprednisolone, or budesonide); an immunosuppressant (e.g., Scyclosporine, tacrolimus, sirolimus, methotrexate, azathioprine, mycophenolate mofetil, leflunomide, cyclophosphamide, 6-mercaptopurine, or antilymphocyte (or antithymocyte) globulin); anti-TNF-α antibodies (e.g., infliximab, adalimumab, certolizumab pegol, or golimumab); anti-IL12 / IL23 antibodies (e.g., ustekinumab); anti-IL6 or anti-IL6R antibodies, anti-IL17 antibodies or small molecule IL12 / IL23 inhibitors (e.g., apilimod); anti-alpha-4-beta-7 antibodies (e.g., vedolizumab); MAdCAM-1 blockers (e.g., PF-00547659); cell adhesion molecule alpha- and combinations comprising one or more active agents selected from the list consisting of antibodies against 4-integrins (e.g., natalizumab); antibodies against the IL2 receptor alpha subunit (e.g., daclizumab or basiliximab); JAK inhibitors, including JAK1 and JAK3 inhibitors (e.g., tofacitinib, baricitinib, R348); Syk inhibitors and their prodrugs (e.g., fostamatinib and R-406); phosphodiesterase-4 inhibitors (e.g., tetomilast); HMPL-004; probiotics; delsalazine; semapimod / CPSI-2364; and protein kinase C inhibitors (e.g., AEB-071).

[0135] For cancer, the further pharmacologic acceptable active ingredients include mitotic inhibitors such as vinblastine, paclitaxel, and docetaxel; alkylating agents such as cisplatin, carboplatin, dacarbazine, and cyclophosphamide; antimetabolites such as 5-fluorouracil, cytosine arabinoside, and hydroxyurea; intercalating agents such as adriamycin and bleomycin; topoisomerase inhibitors such as cyclosporine, cyclosporine, and cyclosporine; Inhibitors, such as etoposide, topotecan, and irinotecan; thymidylate synthase inhibitors, such as raltitrexed; PI3 kinase inhibitors, such as idelalisib; mTor inhibitors, such as everolimus and temsirolimus; proteasome inhibitors, such as bortezomib; histone deacetylase inhibitors, such as panobinostat or vorinostat; and hedgehog pathway blockers such as vismodegib.

[0136] The further pharma- ceutically acceptable active ingredient may be selected from tyrosine kinase inhibitors, such as, for example, axitinib, dasatinib, erlotinib, imatinib, nilotinib, pazopanib, and sunitinib.

[0137] Anti-cancer antibodies may also be included in the combination therapy, such as olaratumumab, daratumumab, or netizumab. , J Nutuximab, traztuzumab emtansine, pertuzumab, obinutuzumab, brentuximab, ofatumumab, panitumumab, catumaxomab, bevacizumab, cetuximab, tositumomab, traztuzumab, gefitinib hmm The agent may be selected from the group consisting of tuzumab ozogamicin and rituximab.

[0138] The compounds or pharmaceutical compositions of the present invention may also be used in combination with radiation therapy.

[0139] Some of the above-mentioned combinations may be conveniently provided for use in the form of pharmaceutical preparations, and thus pharmaceutical preparations comprising the above-defined combinations together with pharma-ceutically acceptable carriers or excipients constitute a further aspect of the invention. The individual components of such combinations may be administered sequentially or simultaneously in separate or combined pharmaceutical preparations. The individual components of the combination may also be administered via the same or different routes.

[0140] When a compound of formula (I) or a pharma- ceutically acceptable derivative thereof is used in combination with a second therapeutic agent active against the same condition, the dose of each compound may differ from the dose when that compound is used alone. Appropriate doses will be readily apparent to those skilled in the art.

[0141] Medical Devices In one embodiment, the compounds of the present invention or pharmaceutical compositions comprising said compounds may be formulated to allow incorporation into a medical device, thus providing for direct application of the compound or composition to the site of interest to prevent or treat a disease as disclosed herein.

[0142] In one embodiment, the compound of the present invention or its pharmaceutical composition is formulated by incorporating it into a coating for a medical device. There are various coatings that can be utilized, such as, for example, polymeric coatings that can release the compound over a period of time. The compound or its pharmaceutical composition can be embedded directly into the medical device. In some embodiments, the compound is coated on or in the device in a delivery vehicle, such as a microparticle or liposome, that facilitates the release and delivery of the compound. In some embodiments, the compound or pharmaceutical composition is miscible in the coating.

[0143] In some embodiments, the medical device is a vascular implant, such as a stent. Stents are used in medical treatment to prevent or eliminate vascular resistance. The implant is inserted into a vessel where resistance occurs, thereby expanding the vessel where resistance occurs. After vessel implantation, excessive proliferation of adjacent cells creates resistance at the vessel, especially at the end of the implant, thereby reducing the effectiveness of the implant. For example, when a vascular implant is inserted into a human artery to eliminate arteriosclerotic stenosis, intimal hyperplasia may occur at the end of the vascular implant within one year, causing new stenosis to occur again (restenosis).

[0144] Thus, in some embodiments, the stent is coated or loaded with a composition comprising a compound of the invention or a pharmaceutical composition thereof, and optionally a targeting signal, a delivery vehicle, or a combination thereof. Many stents are commercially available or otherwise known in the art.

[0145] In some embodiments, the stent is a drug-eluting stent. Various drug-eluting stents are known in the art that provide artificial radial support to vessel wall tissue while simultaneously delivering therapeutic substances to the treatment site. Intraluminal devices, including stents, are sometimes coated on the outer surface with substances such as drug-releasing agents, growth factors, etc. Stents have also been developed that have a hollow tubular structure with holes or ports through the sidewall to allow drugs to be eluted from the central lumen. The hollow nature of the stent allows the central lumen to be filled with a drug solution delivered through the ports or holes in the sidewall of the stent, but the hollow tubular structure may not have adequate mechanical strength to provide a sufficient scaffolding in the blood vessel.

[0146] In some embodiments, the device is also coated with or impregnated with one or more additional therapeutic agents, including, but not limited to, a compound of the invention or a pharmaceutical composition thereof and agents that promote vascular healing and re-endothelialization, such as antiplatelet agents, anticoagulants, anti-inflammatory agents, antimicrobial agents, antimetabolites, additional antineointimal agents, additional antiproliferative agents, immunomodulatory agents, antiproliferative agents, agents that affect migration and extracellular matrix production, agents that affect platelet deposition or thrombus formation, and agents described in Sousa et al. (2003) and Salu et al. (2004).

[0147] Examples of antithrombotic agents include, but are not limited to, heparin (including low molecular weight heparin), R-hirudin, hirulog, argatroban, efegatran, mite anticoagulant peptide, and Ppack.

[0148] Examples of antiproliferative drugs include paclitaxel (Taxol), QP-2, vincristine, methotrexate, angiopeptin, mitomycin, BCP 678, antisense c-myc, ABT 578, actinomycin-D, RestenASE, 1-Chloro-deoxyadenosine ( 1-Chlor-deoxyadenosin ) , PCNA ribozyme, and celecoxib.

[0149] Examples of anti-restenotic drugs include, but are not limited to, sirolimus (rapamycin), tacrolimus, Biorest, mizoribine, cyclosporine, interferon-gamma lb, leflunomide, tranilast, corticosteroids, mycophenolic acid, and immunomodulators such as bisphosphonates.

[0150] Examples of anti-migratory agents and extracellular matrix modulating agents include, but are not limited to, halofuginone, propyl hydroxylase inhibitors, C-proteinase inhibitors, MMP inhibitors, batimastat, and probucol.

[0151] Examples of antiplatelet agents include, but are not limited to, heparin.

[0152] Examples of wound healing and endothelialization promoting agents include vascular endothelial growth factor ("VEGF"), 17-estradiol, Tkase inhibitors, BCP 671, statins, nitric oxide ("NO") donors, and endothelial progenitor cell ("EPC") antibodies.

[0153] Except for coronary applications, drugs and active agents may be incorporated into the stent or stent coating for other indications. For example, in urological applications, antimicrobial agents may be incorporated into the stent or stent coating for the prevention of infection. In gastroenterological and urological applications, active agents may be incorporated into the stent or stent coating for the localized treatment of carcinoma. It may also be advantageous to incorporate contrast agents, radiopaque markers, or other additives into or on the stent so that the stent can be imaged in vivo for tracking, positioning, and other purposes. Such additives may be added to the absorbent composition used to manufacture the stent or stent coating, or to the absorbent composition that is absorbed into, melted on, or sprayed onto part or all of the stent. Preferred additives for this purpose include, but are not limited to, silver, iodine, and iodine-labeled compounds, barium sulfate, gadolinium oxide, bismuth derivatives, zirconium oxide, cadmium, tungsten, gold, tantalum, bismuth, platinum, iridium, and rhodium. These additives may be micron or nano-sized particles or nanoparticles. Radiopacity can be measured by fluoroscopy or x-ray analysis.

[0154] The compounds of the present invention and one or more additional agents, or pharmaceutical compositions thereof, can be incorporated into a stent by loading the compounds and one or more additional agents, or pharmaceutical compositions thereof, into an absorbent material prior to processing, and / or coating the agent(s) on the surface of the stent. The rate of release of the agent can be controlled by a number of methods, including varying the ratio of absorbent material to the compounds and one or more additional agents, or pharmaceutical compositions thereof, the molecular weight of the absorbent material, the composition of the compounds and one or more additional agents, or pharmaceutical compositions, the composition of the absorbent polymer, the thickness of the coating, the number of coating layers and their relative thicknesses, and / or the concentration of the compounds and one or more additional agents, or pharmaceutical compositions. Topcoats of polymers and other materials, including absorbent polymers, may be applied to the active agent coating to control the rate of release. For example, P4HB may be applied as a topcoat over a metallic stent coated with P4HB containing an active agent.

[0155] The present invention is further illustrated by the following non-limiting examples. EXAMPLES

[0156] The abbreviations used herein are defined below. Any abbreviations not defined are intended to have their generally accepted meaning. [Table 1] TIFF0007595593000071.tif242170TIFF0007595593000072.tif232170TIFF0007595593000073.tif103170

[0157] General procedure All starting materials and solvents were obtained from commercial sources or prepared according to the literature. All reactions were carried out under stirring unless otherwise stated. Organic solutions were routinely dried over anhydrous magnesium sulfate. Hydrogenations were carried out in a Thales H-cube flow reactor under the conditions stated.

[0158] Column chromatography was performed on pre-packed silica (230-400 mesh, 40-63 um) cartridges using the amounts indicated. SCX was purchased from Supelco and treated with 1M hydrochloric acid prior to use. Unless otherwise stated, reaction mixtures that needed to be purified were first diluted with MeOH and acidified with a few drops of AcOH. This solution was loaded directly onto the SCX and washed with MeOH. Then, 0.7M NH 3 The desired material was eluted by washing with a solution of MeOH.

[0159] Preparative reversed-phase high-performance liquid chromatography ·Preparative HPLC - Acidic fractionation Waters X-Select CSH column C18, 5um (19 x 50mm), flow rate 28mL / min, H with 0.1% v / v formic acid over 6.5min 2 Elution using an O-MeCN gradient with UV detection at 254 nm.

[0160] Basic separation Waters X-Bridge preparative column C18, 5um (19×50mm), flow rate 28mL / min, 10mM NH over 6.5min 4 HCO 3 -Elution using MeCN gradient, UV detection at 254 nm.

[0161] Analysis method Reversed-phase HPLC conditions for LCMS analytical method

[0162] HPLC acidic: acidic LCMS 4 minutes (5~95%) Analytical LCMS was performed using a Waters X-Select CSH C18, 2.5um, 4.6x30mm column eluting with a gradient of 0.1% formic acid in MeCN / 0.1% formic acid in water. 0.00-3.00 min gradient of 5-95% 0.1% formic acid in MeCN at 2.5mL / min, 3.01-3.5 min flush at 4.5mL / min. 3.60-4.00 min column re-equilibration to 5% MeCN at 2.5mL / min. UV spectra of the eluted peaks were recorded using an Agilent 1260 Infinity VWD at 254nm. Mass spectra were recorded using an Agilent 6120 MSD operated with positive / negative switching.

[0163] HPLC basic: Basic LCMS 4 min (5-95%) Analytical LCMS was performed using a Waters X-Select BEH C18, 2.5um, 4.6x30mm column eluting with a gradient of MeCN / 10mM aqueous ammonium bicarbonate. 0.00-3.00 min gradient of 5-95% MeCN at 2.5mL / min, 3.01-3.5 min flush at 4.5mL / min. 3.60-4.00 min column re-equilibration to 5% MeCN at 2.5mL / min. UV spectra of the eluted peaks were recorded using an Agilent 1260 Infinity VWD at 254nm. Mass spectra were recorded using an Agilent 6120 MSD operated with positive / negative switching.

[0164] Reversed-phase HPLC conditions for UPLC analysis method UPLC acidic: Acidic UPLC 3 minutes Analytical UPLC / MS was performed using a Waters Acquity CSH C18, 1.7um, 2.1 x 30mm column eluting with a gradient of 0.1% formic acid in MeCN / 0.1% formic acid in water. The gradient was built by starting at 5% MeCN and holding this from 0.0-0.11 minutes. A gradient of 5-95% was run from 0.11-2.15 minutes, followed by a flush from 2.15-2.56 minutes. Column re-equilibration to 5% MeCN from 2.56-2.83 minutes. Acquity PD A UV spectra of the eluted peaks were measured using and mass spectra were recorded using an Acquity QDa detector with ESI positive / negative switching.

[0165] Acidic UPLC2 Acidic UPLC 1 minute Analytical UPLC / MS was performed using a Waters Acquity CSH C18, 1.7um, 2.1 x 30mm column eluting with a gradient of 0.1% formic acid in MeCN / 0.1% formic acid in water. The gradient was built by starting at 5% MeCN and holding this from 0.0-0.08 min. A 5-95% gradient from 0.08-0.70 min with a flush from 0.7-0.8 min. Column re-equilibration to 5% MeCN from 0.8-0.9 min. UV spectra of the eluted peaks were measured using an Acquity PDA and mass spectra were recorded using an Acquity QDa detector with ESI positive / negative switching.

[0166] UPLC Basic: Basic UPLC 3 min Analytical UPLC / MS was performed using a Waters Acquity BEH C18, 1.7um, 2.1 x 30mm column eluting with a gradient of MeCN / 10mM aqueous ammonium bicarbonate. The gradient was built by starting at 5% MeCN and holding this from 0.0-0.11 minutes. A gradient of 5-95% was run from 0.11-2.15 minutes, followed by a flush from 2.15-2.56 minutes. Column re-equilibration to 5% MeCN from 2.56-2.83 minutes. UV spectra of the eluted peaks were measured using an Acquity PDA and mass spectra were recorded using an Acquity QDa detector with ESI positive / negative switching.

[0167] Basic UPLC 2 Basic UPLC 1 min Analytical UPLC / MS was performed using a Waters Acquity BEH C18, 1.7um, 2.1 x 30mm column eluting with a gradient of MeCN / 10mM aqueous ammonium bicarbonate. The gradient was built by starting at 5% MeCN and holding this from 0.0-0.08 min. A 5-95% gradient from 0.08-0.70 min with a flush from 0.7-0.8 min. Column re-equilibration to 5% MeCN from 0.8-0.9 min. UV spectra of the eluted peaks were measured using an Acquity PDA and mass spectra were recorded using an Acquity QDa detector with ESI positive / negative switching.

[0168] The column temperature was 40° C. for all measurements. The injection volume was 3 uL and the flow rate was 0.77 mL / min. The PDA scan was from 210 to 400 nm for all measurements.

[0169] · 1 H NMR spectroscopy A 400 MHz Bruker Avance III spectrometer or a 500 MHz Bruker Avance III HD spectrometer were used, using residual undeuterated solvent as the standard. 1 1 H NMR spectra were obtained and measured in DMSO-d6 unless otherwise stated.

[0170] Preparation of intermediates Known synthetic intermediates were obtained from commercial sources or using published literature procedures. Additional intermediates were prepared by the representative synthetic processes described herein.

[0171] Any of methods 1, 2, or 11 (see later herein) or B, C, E, F, J, P, Q, or R can be used in the synthesis of compounds of formula (I). For example, the scheme illustrated using compounds where X=N, Y=CH, and Z=CH can also be used to synthesize compounds where X, Y, and Z are as defined in the claims.

[0172] Preparation of diester intermediates 2-(2-Chloropyrimidin-4-yl)malonic acid 1-(tert-butyl) 3-methyl ester INTC1 [ka] To an ice-cooled, stirred solution of tert-butylmethyl malonate (20.5 mL, 121 mmol) in THF (160 mL) was added NaH (60 wt% in mineral oil, 5.10 g, 128 mmol) in portions. The reaction mixture was stirred at 0° C. for 20 min and then at room temperature for 60 min until hydrogen evolution ceased. 2,4-Dichloropyrimidine (10 g, 67.1 mmol) was then added and the resulting mixture was stirred at 70° C. for 3 h. The reaction mixture was allowed to cool and NH 4 Partitioned between Cl (sat. aq., 500 mL) and EtOAc (500 mL), the two phases were separated, and the organic layer was passed through a phase separator. The crude product was purified by chromatography on silica gel (220 g column, 0-30% EtOAc / isohexane) to give 1-tert-butyl 3-methyl 2-(2-chloropyrimidin-4-yl)malonate (13.1 g, 44.3 mmol, 66% yield) as a clear pale yellow oil; Rt 2.09 min (HPLC acidic); m / z 230 (M+H-tBu). + (ES + ) and 287 (M+H) +(ES + ); 1 H NMR (400 MHz, DMSO-d6) δ 8.83 (d, J = 5.1 Hz, 1H), 7.65 (d, J = 5.1 Hz, 1H), 5.21 (s, 1H), 3.73 (s, 3H), 1.42 (s, 9H).

[0173] Decarboxylation of chloropyrimidines Methyl 2-(2-chloropyrimidin-4-yl)acetate INTC4 [ka] Cool on ice and stir. 2-(2-chloropyrimidin-4-yl) Malonic Acid 1- tert-Butyl 3- To a solution of methyl INTC1 (12.1 g, 42.2 mmol) in DCM (50 mL) was added TFA (55.3 mL, 717 mmol) dropwise. The reaction mixture was stirred at 25° C. for 1 h and then concentrated in vacuo. The residue was dissolved in EtOAc (200 mL) and NaHCO 3 (200 mL), the organic layer was isolated, passed through a phase separator and the solvent removed in vacuo. The crude product was purified by chromatography on silica gel (220 g cartridge, 0-50% EtOAc / isohexane) to give methyl 2-(2-chloropyrimidin-4-yl)acetate (7.12 g, 37.8 mmol, 90% yield) as a pale yellow oil. Rt 1.16 min (HPLC acidic); m / z 187 (M+H). + (ES + ); 1 H NMR (500 MHz, DMSO-d6) δ 8.76 (d, J = 5.0 Hz, 1H), 7.60 (d, J = 5.0 Hz, 1H), 3.96 (s, 2H), 3.66 (s, 3H).

[0174] Method B: Alkylation [ka] To an ice-cooled, stirred mixture of methyl 2-(2-chloropyrimidin-4-yl)acetate in a suitable polar aprotic solvent such as DMF or acetone (10 volumes), a base (2.5-5 equiv.) was added. After 20 min, an alkyl halide (1-5 equiv.) was added. The reactor was stirred at 0° C. for 30 min and then at room temperature for 2 h. The reaction mixture was diluted with NH 4 It was quenched with aqueous Cl or 1M aqueous HCl, stirred for 20 min, then extracted with EtOAc. The organic phase was dried (phase separator) and concentrated. The crude product was purified by normal phase chromatography. [Table 2]

[0175] Heterocycle formation by alkylation Methyl 4-(2-chloropyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxylate INTC52 [ka] To a solution of methyl 2-(2-chloropyrimidin-4-yl)acetate INTC4 (2.0 g, 10.7 mmol) in DMF (10 mL, 10.7 mmol) at 0° C. was added NaOH (0.986 g, 24.6 mmol). The reaction mixture was stirred at 0° C. for 20 min, then 1-bromo-2-(2-bromoethoxy)ethane (1.8 mL, 12.9 mmol) was added. The reaction mixture was stirred at room temperature for 23 h. The reaction mixture was acidified with 1 M HCl (aq, 53.6 mL, 53.6 mmol) and then extracted with DCM (70 mL). The phases were separated using a phase separator cartridge and the aqueous phase was further extracted with DCM (2×50 mL). The combined organics were concentrated in vacuo. The crude product was purified by chromatography on silica gel (80 g column, 0-50% EtOAc / isohexane) to give methyl 4-(2-chloropyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxylate (1.83 g, 5.57 mmol, 52% yield) as a yellow oil. Rt 1.56 min (HPLC, acidic); m / z 257 ( 35Cl M+H) + (ES + ); 1 H NMR (500 MHz, DMSO-d6) δ 8.80 (d, J = 5.3 Hz, 1H), 7.69 (d, J = 5.3 Hz, 1H), 3.72-3.67 (m, 2H), 3.66 (s, 3H), 3.55-3.50 (m, 2H), 2.33 - 2.22 (m, 2H), 2.16 - 2.06 (m, 2H).

[0176] Enolates S N Heterocycle formation by AR 4-(2-chloropyrimidin-4-yl)piperidine-1,4-dicarboxylate 1-tert-butyl 4-methyl INTC66 [ka] To an ice-cooled, stirred solution of 1-tert-butyl 4-methyl piperidine-1,4-dicarboxylate (340 mg, 1.40 mmol) and 2,4-dichloropyrimidine (200 mg, 1.34 mmol) in THF (10 mL) was added LiHMDS (1.61 mL, 1.61 mmol) in one portion. The reaction mixture was allowed to warm to room temperature and stirred for 2 h. The reaction mixture was diluted with NaH 2 PO 4 (aq, 1M, 3 mL). The product was extracted with DCM (2×10 mL). The combined organic extracts were dried through a hydrophobic phase separator and concentrated in vacuo. The crude product was purified by chromatography on silica gel (24 g column, 0-50% EtOAc / isohexane) to give 1-tert-butyl 4-methyl 4-(2-chloropyrimidin-4-yl)piperidine-1,4-dicarboxylate (315 mg, 0.66 mmol, 49% yield) as a colorless oil. Rt 2.29 min (HPLC, acidic); m / z 255 ( 35 Cl M-Boc+H) + (ES + ); 1H NMR (500 MHz, DMSO-d6) δ 8.79 (d, J = 5.3 Hz, 1H), 7.68 (d, J = 5.3 Hz, 1H), 3.69 - 3.59 (m, 5H), 3.13 (s, 2H), 2.26 - 2.22 (m, 2H), 2.06 - 2.00 (m, 2H), 1.40 (s, 9H).

[0177] Method C: Formation of sulfonamides from aromatic halides [ka] The 2-chloropyrimidine intermediate (1 eq.), sulfonamide (1.2 eq.), and base (2 eq.) were dissolved in dioxane (40 vol.). The mixture was degassed (N 2 , 5 min), followed by addition of catalyst (5 mol%) as required. The resulting mixture was heated at 90° C. under nitrogen for 2 h. The mixture was filtered, washed with EtOAc or DCM, and the filtrate was concentrated. The crude product was purified by normal phase chromatography or trituration with an appropriate solvent. [Table 3] TIFF0007595593000082.tif238170

[0178] Tetrahydropyran derivatives via thioethers Methyl 4-(2-(methylthio)pyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxylate INTC178 [ka] To a solution of 4-chloro-2-(methylthio)pyrimidine (0.55 g, 3.42 mmol) and methyl tetrahydro-2H-pyran-4-carboxylate (494 mg, 3.42 mmol) in THF (5 mL) at 30° C., LiHMDS (1 M in THF) (4.11 mL, 4.11 mmol) was added dropwise. The reaction mixture was stirred at 30° C. for 5 min, then poured into water (100 mL) and extracted with EtOAc (2×200 mL). The organic extract was washed with saturated brine (1×100 mL), dried (MgSO 4 ), filtered and the solvent removed in vacuo to give methyl 4-(2-(methylthio)pyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxylate (915 mg, 3.24 mmol, 95% yield) as a pale yellow oil. Rt 1.74 min (HPLC acidic); m / z 269 (M+H) + (ES + ); 1 H NMR (500 MHz, DMSO-d6) δ 8.62 (d, J = 5.3 Hz, 1H), 7.27 (d, J = 5.3 Hz, 1H), 3.76-3.70 (m, 2H), 3.67 (s, 3H), 3.54-3.46 (m, 2H), 2.49 (s, 3H), 2.27-2.20 (m, 2H), 2.14-2.04 (m, 2H).

[0179] Methyl 4-(2-(methylsulfonyl)pyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxylate INTC179 [ka] To a stirred solution of methyl 4-(2-(methylthio)pyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxylate INTC178 (915 mg, 3.24 mmol) in DCM (50 mL) was added mCPBA (1.60 g, 7.13 mmol) dropwise and the resulting reaction mixture was stirred at room temperature for 3 h. The reaction mixture was diluted with saturated NaHCO 3 (aqueous, 200 mL) and extracted with DCM (3×100 mL). The organic extracts were washed with saturated NaHCO 3(aqueous solution, 100 mL) and saturated saline (100 mL), then dehydrated (MgSO 4 ), filtered and the solvent removed in vacuo to give methyl 4-(2-(methylsulfonyl)pyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxylate (1.10 g, 3.30 mmol, quantitative yield) as a thick gum. Rt 1.20 min (HPLC acidic); m / z 301 (M+H) + (ES + ); 1 H NMR (500 MHz, DMSO-d6) δ 9.09 (d, J = 5.3 Hz, 1H), 7.95 (d, J = 5.3 Hz, 1H), 3.77-3.70 (m, 2H), 3.68 (s, 3H), 3.60-3.49 (m, 2H), 3.42 (s, 3H), 2.34-2.24 (m, 2H), 2.23 -2.13 (m, 2H).

[0180] ·Methyl 4-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxylate INTC53 [ka] Methyl 4-(2-(methylsulfonyl)pyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxylate. To a solution of INTC179 (1.0 g, 3.33 mmol) and cyclopropanesulfonamide (0.52 g, 4.33 mmol) in NMP (100 mL) was added cesium carbonate (3.25 g, 9.99 mmol) and heated at 90° C. for 1 h. The reaction mixture was cooled to room temperature, diluted with water (100 mL), the mixture was washed with MTBE (2×100 mL), and the aqueous layer was slowly acidified to pH 3 with dilute HCl (20 mL). The resulting precipitate was filtered to give methyl 4-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxylate (755 mg, 2.21 mmol, 66% yield) as a colorless solid. Rt. 0.88 (UPLC, acidic), m / z 342 (M+H) + (ES + );1 H NMR (500 MHz, DMSO-d6) δ 11.30 (s, 1H), 8.60 (d, J = 5.3 Hz, 1H), 7.20 (d, J = 5.3 Hz, 1H), 3.79-3.72 (m, 2H), 3.67 (s, 3H), 3.52-3.44 (m, 2H), 3.25 - 3.14 (m, 1H), 2.30 - 2.17 (m, 2H), 2.12-2.04 (m, 2H), 1.14 - 1.01 (m, 4H).

[0181] Method J: Hydrolysis [ka] To a solution of the ester (1 eq) in MeOH (3 vol) and THF (3 vol) was added 2M LiOH (aq, 2 eq) and the resulting reaction mixture was stirred at 50° C. for 2 h. The solvent was removed under reduced pressure and then acidified to pH 3 with 1M HCl (aq). The solution was extracted with EtOAc, the organic phase was passed through a phase separator and the solvent was removed. The compound was used crude or purified by reverse phase chromatography.

[0182] Alkylation Methyl 1-(2-chloropyrimidin-4-yl)cyclopropanecarboxylate INTC146 [equivalent to INTC13] [ka] To a solution of methyl 2-(2-chloropyrimidin-4-yl)acetate (3 g, 16.08 mmol) in DMF (40 mL) was added NaOH (1.93 g, 48.2 mmol). The resulting mixture was stirred at room temperature for 15 min, then 1,2-dibromoethane (2.77 mL, 32.2 mmol) was added dropwise and stirred at room temperature for 3 h. The mixture was diluted with saturated NH 4 Cl (aq, 100 mL) and diluted with EtOAc (40 mL). The phases were separated and the aqueous phase was extracted with EtOAc (2×40 mL). The combined organic layers were dried (Na 2 SO 4), filtered and the solvent removed in vacuo. The crude product was purified by chromatography on silica gel (120 g column, 0-50% EtOAc / isohexane) to give methyl 1-(2-chloropyrimidin-4-yl)cyclopropanecarboxylate (1.78 g, 8.12 mmol, 51% yield) as a colorless oil. Rt 1.05 min (UPLC, basic); m / z 213 (M+H) + (ES + ); 1 H NMR (500 MHz, DMSO-d6) δ 8.70 (d, J = 5.2 Hz, 1H), 7.88 (d, J = 5.2 Hz, 1H), 3.67 (s, 3H), 1.68 - 1.63 (m, 2H), 1.59 (dt, J = 5.1, 2.9 Hz, 2H).

[0183] Hydrolysis 1-(2-Chloropyrimidin-4-yl)cyclopropanecarboxylic acid INTC147 [ka] Methyl 1-(2-chloropyrimidin-4-yl)cyclopropanecarboxylate Prepared by Method J using INTC146 to give 1-(2-chloropyrimidin-4-yl)cyclopropanecarboxylic acid (quantitative yield) as a colorless solid. Rt 0.83 min (UPLC acidic); m / z 199 (M+H) + (ES + ) No NMR data were recorded.

[0184] Curtius tert-Butyl (1-(2-chloropyrimidin-4-yl)cyclopropyl)carbamate INTC148 [ka] A solution of 1-(2-chloropyrimidin-4-yl)cyclopropanecarboxylic acid INTC147 (1.85 g, 9.31 mmol) in tert-butanol (15 mL) and toluene (15 mL) was added with Et 3N (1.49 mL, 10.3 mmol) and DPPA (2.23 mL, 9.78 mmol) were added successively. The resulting mixture was stirred at 90° C. for 4 h. The mixture was cooled to room temperature and saturated NaHCO 3 (aqueous, 50 mL) and diluted with EtOAc (30 mL). The phases were separated and the aqueous layer was extracted with EtOAc (3×20 mL). The combined organic layers were dried (Na 2 SO 4 ), filtered and the solvent removed in vacuo. The crude product was purified by chromatography on silica gel (120 g column, 0-50% EtOAc / isohexane) to give tert-butyl (1-(2-chloropyrimidin-4-yl)cyclopropyl)carbamate (1.02 g, 3.33 mmol, 36% yield) as a colorless solid. Rt 1.26 min (UPLC acidic); m / z 270 (M+H) + (ES + ). 1 H NMR (500 MHz, DMSO-d6) δ 8.63 (d, J = 5.3 Hz, 1H), 7.91 (s, 1H), 7.38 (d, J = 5.3 Hz, 1H), 1.42 (s, 9H), 1.35 - 1.21 (m, 4H).

[0185] Formation of sulfonamides from aromatic halides [Table 4]

[0186] ·Deprotection: Boc ·N-(4-(1-aminocyclopropyl)pyrimidin-2-yl)cyclopropanesulfonamide hydrochloride INTC156 [ka] tert-Butyl (1-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)cyclopropyl)carbamate. To a solution of INTC153 (200 mg, 0.564 mmol) in dioxane (2 mL) was added HCl (4 M in dioxane) (1.41 mL, 5.64 mmol) and the resulting solution was stirred at room temperature for 18 h. The solvent was removed in vacuo to give N-(4-(1-aminocyclopropyl)pyrimidin-2-yl)cyclopropanesulfonamide hydrochloride (164 mg, 0.564 mmol, quantitative yield) as a slightly yellow solid which was used without any further purification. Rt 0.39 min (UPLC acidic); m / z 255 (M+H) + (ES + ) No NMR data were collected.

[0187] Preparation of amine intermediates Method E: Suzuki coupling of haloanilines with heteroaromatic boronates [ka] In solvent (3 volumes) Ar1-X (1 equivalent) and Ar2-Z (1 equivalent), And base( 2.5 equivalent weight )of The solution was degassed (N 2 , 5 min), heated to 40 °C, whereupon Pd catalyst (3 mol%) was added and the reaction mixture was further degassed (N 2 , 5 min) and then heated at 90° C. for 90 min. The reaction mixture was allowed to cool to room temperature. Typically, the desired compound was purified by column chromatography.

[0188] Method F: Suzuki coupling of heteroaromatic halides with aniline boronates [ka] Degassed (N 2To a solution of Ar1-X (1 equiv.), Ar2-Z (1 equiv.), and base (3 equiv., 6.85 mmol) in solvent (3 volumes) was added Pd catalyst (5 mol%). The solution was then further degassed (N 2 , 5 min), then heated at 90° C. for 2 h and then allowed to cool to room temperature. Typically, the desired compounds were purified by column chromatography.

[0189] Aniline [Table 5]

[0190] (5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)methanol INTD84 [ka] A suspension of (5-bromopyridin-2-yl)methanol (1.00 g, 5.32 mmol), Bispin (1.5 g, 5.91 mmol), and KOAc (1.6 g, 16.0 mmol) in dioxane (20 mL) was heated at 30 °C and then degassed (N 2 ).PdCl 2 (dppf)-CH 2 Cl 2 (0.217 g, 0.266 mmol) was added and the reaction mixture was heated at 90° C. for 2 h. The reaction mixture was cooled to 40° C. and immediately added 2-chloro-6-ethoxypyrazine (900 mg, 5.68 mmol), Cs 2 CO 3 (3.47 g, 10.6 mmol), and water (5 mL) were added. The mixture was degassed (N 2 ), followed by PdCl 2 (dppf)-CH 2 Cl 2 (0.217 g, 0.266 mmol) was added and the mixture was degassed again (N 2). The reaction mixture was then heated at 90° C. for 18 h. The reaction mixture was partially concentrated (to approximately 5 mL) and then stripped with water (20 mL) and EtOAc (50 mL), passed through Celite, and eluted with EtOAc (20 mL). The phases were then diluted with water (20 mL) and partitioned. The organic phase was washed with saturated brine (30 mL), dried (Na 2 SO 4 ), filtered and concentrated onto silica (5 g). The crude product was purified by chromatography on silica (40 g cartridge, 0-100% EtOAc / isohexane) to give (5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)methanol (675 mg, 2.86 mmol, 54% yield) as a brown solid. Rt 1.24 min (HPLC, acidic); m / z 232 (M+H) + (ES + ); 1 H NMR (500 MHz, DMSO-d6) δ 9.27 - 9.09 (m, 1H), 8.87 (s, 1H), 8.49 (dd, J = 8.2, 2.3 Hz, 1H), 8.29 (s, 1H), 7.62 (d, J = 8.2 Hz, 1H), 5.53 (t, J = 5.9 Hz, 1H), 4.64 (d, J = 5.9 Hz, 2H), 4.50 (q, J = 7.1 Hz, 2H), 1.41 (t, J = 7.1 Hz, 3H).

[0191] 5-(6-ethoxypyrazin-2-yl)picolinaldehyde INTD85 [ka] (5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)methanol INTD84 (375 mg, 3.18 mmol) 2 Cl 2The (15 mL) solution was treated with manganese dioxide (3 g, 34.5 mmol). The reaction mixture was stirred at room temperature for 4 h, then filtered through Celite and concentrated onto silica (4 g). The crude product was purified by chromatography on silica (24 g cartridge, 0-100% EtOAc / isohexane) to give 5-(6-ethoxypyrazin-2-yl)picolinaldehyde (309 mg, 1.32 mmol, 42% yield) as a colorless solid. Rt 1.85 min (HPLC, acidic); m / z 230 (M+H) + (ES + ); 1 H NMR (500 MHz, DMSO-d 6 ) δ 10.07 (d, J = 0.8 Hz, 1H), 9.55 (dd, J = 2.2, 0.9 Hz, 1H), 9.03 (s, 1H), 8.73 (ddd, J = 8.1, 2.2, 0.8 Hz, 1H), 8.39 (s, 1H), 8.08 (dd, J = 8.1, 0.9 Hz, 1H), 4.53 (q, J = 7.0 Hz, 2H), 1.42 (t, J = 7.0 Hz, 3H).

[0192] 5-(6-ethoxypyrazin-2-yl)picolinic acid INTD86 [ka] 5-(6-Ethoxypyrazin-2-yl)picolinaldehyde. A solution of INTD85 (302 mg, 1.32 mmol) in DMF (5 mL) was treated with oxone (1.02 g, 1.66 mmol). The reaction mixture was stirred at room temperature for 4 days. The reaction mixture was diluted with water (10 mL) and filtered. The filtrate was then scooped into EtOAc (10 mL) and heated at 40° C. to give a free-flowing suspension. It was then treated dropwise with isohexane (10 mL), cooled to room temperature, and filtered to give 5-(6-ethoxypyrazin-2-yl)picolinic acid (240 mg, 0.93 mmol, 71% yield) as a colorless solid. Rt 1.45 min (HPLC, acidic); m / z 246 (M+H) + (ES +); 1 H NMR (500 MHz, DMSO-d 6 ) δ 13.31 (s, 1H), 9.46 - 9.38 (m, 1H), 8.98 (s, 1H), 8.64 (dd, J = 8.1, 2.3 Hz, 1H), 8.36 (s, 1H), 8.17 (dd, J = 8.1, 0.8 Hz, 1H), 4.51 (q, J = 7.0 Hz, 2H), 1.42 (t, J = 7.0 Hz, 3H).

[0193] -Carbocycle formation by alkylation Methyl 1-(2-chloropyrimidin-4-yl)cyclohexanecarboxylate INTC180 [ka] To a solution of methyl 2-(2-chloropyrimidin-4-yl)acetate (0.98 g, 4.73 mmol) in MeCN (0.25 mL) at room temperature was added cesium carbonate (3.08 g, 9.45 mmol) in portions. The reaction mixture was heated at 60° C. 1,5-dibromopentane (0.77 mL, 5.67 mmol) was added dropwise over 15 min to the reaction mixture and the reaction mixture was heated at 70° C. for 2 h and then cooled to room temperature. The reaction mixture was diluted with water (100 mL) and MTBE (100 mL). The phases were separated. The combined organics were dried (MgSO 4 ), filtered and concentrated in vacuo. The crude product was purified by chromatography on silica gel (24 g cartridge, 0-50% EtOAc / isohexane) to give methyl 1-(2-chloropyrimidin-4-yl)cyclohexanecarboxylate (858 mg, 71%) as a colorless oil; Rt 2.23 min (HPLC acidic); m / z 255 (M+H). + (ES + ). 1H NMR (500 MHz, DMSO-d6) δ 8.76 (d, J = 5.2 Hz, 1H), 7.63 (d, J = 5.2 Hz, 1H), 3.64 (s, 3H), 2.24 - 2.16 (m, 2H), 1.97 - 1.88 (m, 2H), 1.60 - 1.49 (m, 4H), 1.49 - 1.26 (m, 2H).

[0194] Ethyl 1-(6-chloropyrazin-2-yl)cyclohexane-1-carboxylate INTC181 [ka] Prepared as for INTC180 using ethyl 2-(6-chloropyrazin-2-yl)acetate (0.82 g, 4.09 mmol) and stirring at 70 °C for 3 h to give ethyl 1-(6-chloropyrazin-2-yl)cyclohexane-1-carboxylate (423 mg, 1.49 mmol, 37% yield) as a colorless solid; Rt 2.55 min (HPLC acidic); m / z 269 (M+H). + (ES + ). 1 H NMR (500 MHz, DMSO-d6) δ 8.76 (s, 1H), 8.72 (s, 1H), 4.11 (q, J = 7.1 Hz, 2H), 2.30 - 2.20 (m, 2H), 2.02 - 1.94 (m, 2H), 1.60 - 1.41 (m, 5H), 1.39-1.29 (m, 1H), 1.12 (t, J = 7.1 Hz, 3H).

[0195] ·N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylthio)pyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxamide INTC182 [ka] Prepared using Method 11 using methyl 4-(2-(methylthio)pyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxylate INTC178 (1.0 equiv), 5-(6-ethoxypyrazin-2-yl)pyridin-2-amine INTD33 (1.0 equiv), and i-PrMgCl (2.0 equiv) to give N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylthio)pyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxamide (5.5 g, 11.67 mmol, 48% yield) as a pale yellow solid; Rt 2.35 min (HPLC acidic); m / z 453 (M+H). + (ES + ). 1 H NMR (500 MHz, DMSO-d6) δ 10.20 (s, 1H), 9.05 (dd, J = 2.5, 0.8 Hz, 1H), 8.85 (s, 1H), 8.64 (d, J = 5.3 Hz, 1H), 8.51 (dd, J = 8.8, 2.5 Hz, 1H), 8.26 (s, 1H), 8.21 (dd, J = 8.7, 0.8 Hz, 1H), 7.33 (d, J = 5.3 Hz, 1H), 4.48 (q, J = 7.0 Hz, 2H), 3.77-3.70 (m, 2H), 3.65-3.58 (m, 2H), 2.54-2.44 (m, 5H, obscured by DMSO peak), 2.25-2.17 (m, 2H), 1.40 (t, J = 7.0 Hz, 3H).

[0196] Method P: SNAR using 4-chloro-2-(methylthio)-heterocyclic compounds [ka] A solution of heteroaromatic chloride (1 equiv.) and ester (1 equiv.) in THF (5-20 volumes) was warmed to 30°C and LiHMDS (1.25 equiv., 1-1.5 M in THF) was added. The reaction mixture was stirred at this temperature for up to 3 h, then poured into water and extracted with EtOAc. The organic extract was washed with brine, dried (MgSO 4), filtration and removal of the solvent in vacuo afforded the desired compound. If necessary, the crude product was purified by normal phase chromatography. [Table 6]

[0197] Lithium 4-(2-(methylthio)pyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxylate INTC193 [ka] Methyl 4-(2-(methylthio)pyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxylate (2 g, 7.45 mmol). To a solution of INTC178 in THF (10 mL) was added a solution of lithium hydroxide monohydrate (0.38 g, 8.94 mmol) in water (5 mL). The resulting mixture was stirred at room temperature for 7 days. The reaction mixture was diluted with EtOAc (5 mL) and water (5 mL), the phases were separated, and the aqueous phase was washed with additional EtOAc (5 mL). The aqueous phase was concentrated in vacuo to give lithium 4-(2-(methylthio)pyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxylate (1.85 g, 6.75 mmol, 91% yield) as a colorless solid, which was used without further purification. Rt 0.48 min (UPLC 2, acidic); m / z 255 (CO 2 H+H) + (ES + ). 1 No 1 H NMR data was collected.

[0198] Curtius ·(4-(2-(methylthio)pyrimidin-4-yl)tetrahydro-2H-pyran-4-yl)carbamic acid tert-butyl ester INTC194 [ka] Lithium 4-(2-(methylthio)pyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxylate. Prepared as for INTC148 using INTC193 (2.5 g, 8.65 mmol) and T3P (50 wt % in EtOAc) (0.78 mL, 10.38 mmol) and stirring at 90° C. for 18 h to give tert-butyl (4-(2-(methylthio)pyrimidin-4-yl)tetrahydro-2H-pyran-4-yl)carbamate (214 mg, 0.605 mmol, 7% yield) as a colorless oil; Rt 1.22 min (UPLC acidic); m / z 326 (M+H). + (ES + ). 1 H NMR (500 MHz, DMSO-d6) δ 8.58 (d, J = 5.3 Hz, 1H), 7.51 (s, 1H), 7.12 (d, J = 5.3 Hz, 1H), 3.78 - 3.56 (m, 4H), 2.52 (s, 3H), 2.09 - 2.00 (m, 4H), 1.37 (s, 9H).

[0199] 4-(2-(methylthio)pyrimidin-4-yl)tetrahydro-2H-pyran-4-amine·HCl INTC195 [ka] tert-Butyl (4-(2-(methylthio)pyrimidin-4-yl)tetrahydro-2H-pyran-4-yl)carbamate. Prepared as for INTC156 using INTC194 to give 4-(2-(methylthio)pyrimidin-4-yl)tetrahydro-2H-pyran-4-amine·HCl (210 mg, 0.698 mmol, quantitative yield) as a colorless solid; Rt 0.43 min (UPLC basic); m / z 226 (M+H). + (ES + ). 1H NMR (500 MHz, DMSO-d6) δ 8.92 - 8.81 (m, 2H), 8.78 (d, J = 5.3 Hz, 1H), 7.59 (d, J = 5.3 Hz, 1H), 3.95 - 3.86 (m, 2H), 3.59 - 3.49 (m, 2H), 2.59 (s, 3H), 2.41 - 2.33 (m, 2H), 2.04 - 1.96 (m, 2H).

[0200] Amide formation ·5-(6-ethoxypyrazin-2-yl)-N-(4-(2-(methylthio)pyrimidin-4-yl)tetrahydro-2H-pyran-4-yl)picolinamide INTC196 [ka] Prepared using Method 1 using 4-(2-(methylthio)pyrimidin-4-yl)tetrahydro-2H-pyran-4-amine hydrochloride INTC195 (1.0 equiv.) and 5-(6-ethoxypyrazin-2-yl)picolinic acid INTD86 (1.1 equiv.) to give 5-(6-ethoxypyrazin-2-yl)-N-(4-(2-(methylthio)pyrimidin-4-yl)tetrahydro-2H-pyran-4-yl)picolinamide (35% yield) as a colorless oil. Rt 0.66 min (UPLC acidic); m / z 454 (M+H). + (ES + ). 1H NMR (500 MHz, DMSO-d6) δ 9.45 (dd, J = 2.2, 0.8 Hz, 1H), 9.01 - 8.97 (m, 2H), 8.69 (dd, J = 8.2, 2.2 Hz, 1H), 8.56 (d, J = 5.3 Hz, 1H), 8.38 (s, 1H), 8.09 (dd, J = 8.2, 0.8 Hz, 1H), 7.23 (d, J = 5.3 Hz, 1H), 4.53 (q, J = 7.0 Hz, 2H), 3.87 - 3.81 (m, 2H), 3.71 - 3.63 (m, 2H), 3.17 (d, J = 5.2 Hz, 3H), 2.41 - 2.35 (m, 2H), 2.28 - 2.18 (m, 2H), 1.43 (t, J = 7.0 Hz, 3H).

[0201] Method Q: Oxidation of thioethers to sulfones or sulfoxides [ka] To a stirred solution of the thioether (1 equiv.) in DCM (20-50 vol.), mCPBA (2.2 equiv.) was added portionwise while maintaining the internal temperature at room temperature. The resulting mixture was stirred at room temperature for an additional 3 h. This reaction mixture was diluted with saturated Na 2 SO 3 The organic extract was poured into aqueous solution of saturated NaHCO 3 The mixture was washed successively with aqueous solution and saturated saline, dehydrated (MgSO 4 ), filtered and the solvent removed in vacuo to give the desired compound. [Table 7] TIFF0007595593000109.tif182170

[0202] [Table 8]

[0203] 4-(4-(cyclopropanesulfonamido)pyrimidin-2-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)piperidine-4-carboxamide hydrochloride INTC247 [ka] This compound was prepared by Boc deprotection of INTC246 with HCl; [HPLC acidic], 521, (1.30).

[0204] Preparation of Examples Amide formation Method 1: Amide coupling using HATU [ka] Add the above acid or potassium salt (1 equivalent, X 2 =CO 2 H or CO 2 To a suspension of 1M NaOH (aq) and DIPEA (6 eq) in DMF (15 vol.) was added the above aniline or amine (1 eq) and HATU (1.5 eq.). The reaction mixture was stirred at room temperature for 18 h then concentrated in vacuo. MeOH and 2M NaOH (aq.) were added. The mixture was stirred for 30 min then concentrated in vacuo. The aqueous phase was acidified to pH 6 with 1M HCl (aq.) and the product was extracted into DCM. The organics were combined, dried (phase separator) and concentrated in vacuo. The crude product was purified by normal or reverse phase chromatography or a combination of both.

[0205] Method 2: AlMe from esters 3 Mediated Amide Coupling [ka] To an ice-cold solution of aniline (2 equivalents) in toluene (40 volumes), add AlMe 3(2.0M in heptane, 2 eq.) was added. The mixture was stirred at this temperature for 5 min, then at room temperature for 10 min. To this solution was added the ester (1 eq.) in one portion, and the resulting mixture was heated and stirred at 80° C. for 2 h. The reaction mixture was cooled in an ice bath and carefully quenched with MeOH (10 vol.). After stirring for 20 min, the mixture was diluted in a mixture of DCM / MeOH (10 vol.), filtered through Celite, and the filtrate was concentrated. The crude product was purified by reverse or normal phase chromatography.

[0206] Method 11: i-PrMgCl-mediated amide coupling from esters [ka] To an ice-cold solution of aniline (1.1 equiv) in THF (10-50 vol) was added i-PrMgCl (2.0 M in THF, 2.0 equiv) dropwise over 5-15 min to maintain the internal temperature below 10 °C. The reaction mixture was allowed to warm to room temperature over 45 min, then the ester (1.0 equiv) in THF (5-20 vol) was added dropwise over 5-15 min. The reaction mixture was stirred at ambient temperature for 5-15 min, then more i-PrMgCl (2.0 M in THF, 2.0 equiv) was added dropwise over 5-20 min. The reaction mixture was stirred at room temperature for 30 min, then the solution was slowly poured into 1 M HCl (aq) and extracted with EtOAc. The organics were combined, dried (phase separator), and concentrated in vacuo. The crude product was purified by reverse or normal phase chromatography or a combination of both.

[0207] Method R: Formation of sulfonamides from aromatic sulfones [ka] To a solution of sulfone (1.0 equiv) and primary sulfonamide (1.1-2.0 equiv) in a polar aprotic solvent such as NMP (5-100 vol), an inorganic base such as cesium carbonate (3 equiv) was added and heated at 40-90°C for 1-3 h. The reaction mixture was cooled to room temperature, diluted with water (50-100 vol), the mixture was washed with MTBE (100 vol) and the aqueous phase was acidified to pH 5 with a suitable acid such as HCl. The resulting precipitate was filtered to give the desired sulfonamide product.

[0208] ·4-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-1-methylpiperidine-4-carboxamide P231 [ka] 4-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)piperidine-4-carboxamide hydrochloride To a solution of P140 (0.1 g, 0.178 mmol) in DCM (2 mL) was added AcOH (0.1 mL, 1.75 mmol) and formaldehyde (0.1 mL, 1.34 mmol). The reaction mixture was stirred at room temperature for 1 h and then NaBH(OAc) 3 (0.113 g, 0.535 mmol) was added and stirring was continued for 20 h. The reaction mixture was concentrated in vacuo and purified by chromatography on RP Flash C18 (12 g column, 25-60% MeCN / water 0.1% formic acid) to give 4-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-1-methylpiperidine-4-carboxamide (28 mg, 0.051 mmol, 29% yield) as a colorless solid. Rt 0.83 min (UPLC, acidic); m / z 539 (M+H) + (ES + ); 1H NMR (500 MHz, DMSO-d6) δ 9.97 (s, 1H), 9.02 (d, J = 2.4 Hz, 1H), 8.83 (s, 1H), 8.54 - 8.46 (m, 2H), 8.25 (s, 1H), 8.21 - 8.14 (m, 1H), 7.12 - 7.07 (m, 1H), 4.48 (q, J = 7.1 Hz, 2H), 3.24 - 3.17 (m, 1H), 2.50 - 2.43 (m, 4H), 2.39 - 2.25 (m, 2H), 2.25 - 2.16 (m, 2H), 2.15 (s, 3H), 1.40 (t, J = 7.0 Hz, 3H), 1.03 - 0.97 (m, 2H), 0.87 - 0.80 (m, 2H). One exchangeable proton is not observed.

[0209] 4-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-1-isopropylpiperidine-4-carboxamide P232 [ka] 4-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)piperidine-4-carboxamide hydrochloride P140 and acetonitrile hmm Prepared similarly as for P231 using 4-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-1-isopropylpiperidine-4-carboxamide (20% yield) as a colorless solid. Rt 0.88 min (UPLC, acidic); m / z 567 (M+H) + (ES+); 1H NMR (500 MHz, DMSO-d6) δ 9.78 (s, 1H), 9.02 (d, J = 2.4 Hz, 1H), 8.81 (s, 1H), 8.46 (dd, J = 8.7, 2.4 Hz, 1H), 8.23 ​​(s, 1H), 8.19 (d, J = 5.0 Hz, 1H), 8.10 (d, J = 8.7 Hz, 1H), 6.53 (s, 1H), 4.47 (q, J = 7.0 Hz, 2H), 3.03 - 2.99 (m, 1H), 2.62 - 2.54 (m, 1H), 2.45 - 2.37 (m, 2H), 2.34 - 2.29 (m, 3H), 2.28 - 2.17 (m, 2H), 1.39 (t, J = 7.0 Hz, 3H), 0.91 (d, J = 6.5 Hz, 6H), 0.81 - 0.76 (m, 2H), 0.63 - 0.58 (m, 2H). One exchangeable proton was not observed and one proton was obscured by the DMSO peak.

[0210] 4-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)-N4-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-N1-isopropylpiperidine-1,4-dicarboxamide P233 [ka] 4-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)piperidine-4-carboxamide hydrochloride To a solution of P140 (0.1 g, 0.178 mmol) in DCM (2 mL) was added TEA (0.08 mL, 0.57 mmol) and isopropyl isocyanate (0.02 mL, 0.187 mmol). The reaction mixture was stirred at room temperature for 24 h. The reaction mixture was concentrated in vacuo and purified by chromatography on RP Flash C18 (12 g cartridge, 5-50% MeCN / 10 mM ammonium bicarbonate) to give 4-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)-N4-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-N1-isopropylpiperidine-1,4-dicarboxamide (69 mg, 0.111 mmol, 62% yield) as a colorless solid. Rt 1.31 min (UPLC, acidic); m / z 610 (M+H). + (ES + ); 1 H NMR (500 MHz, DMSO-d6) δ 11.29 (s, 1H), 10.13 (s, 1H), 9.02 (d, J = 2.5 Hz, 1H), 8.84 (s, 1H), 8.61 (d, J = 5.3 Hz, 1H), 8.50 (dd, J = 8.8, 2.5 Hz, 1H), 8.25 (s, 1H), 8.18 (d, J = 8.8 Hz, 1H), 7.23 (d, J = 5.3 Hz, 1H), 6.18 (d, J = 6.5 Hz, 1H), 4.48 (q, J = 7.0 Hz, 2H), 3.75 (h, J = 6.5 Hz, 1H), 3.68 - 3.61 (m, 2H), 3.28 - 3.21 (m, 1H), 3.19 - 3.11 (m, 2H), 2.46 - 2.41 (m, 2H), 2.11 - 2.02 (m, 2H), 1.40 (t, J = 7.0 Hz, 3H), 1.09 - 1.03 (m, 8H), 0.91 - 0.84 (m, 2H).

[0211] 1-Acetyl-4-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)piperidine-4-carboxamide P234 [ka] 4-(2-(Cyclopropanesulfonamido)pyrimidin-4-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)piperidine-4-carboxamide hydrochloride Prepared similarly to P233 using P140 and acetic anhydride. The crude material was purified by chromatography on silica gel (12 g cartridge, 0-100% EtOAc / isohexane then flush with 10% MeOH / DCM) to give a brown oil which was dissolved in MeCN (1 mL) and MTBE added until precipitation occurred. The precipitate was isolated by filtration and washed with additional MTBE (2×10 mL) to give 1-acetyl-4-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)piperidine-4-carboxamide (51 mg, 0.088 mmol, 24% yield) as a light brown solid. Rt 1.20 min (UPLC, acidic); m / z 567 (M+H). + (ES + ); 1H NMR (500 MHz, DMSO-d6) δ 11.30 (s, 1H), 10.23 (s, 1H), 9.03 (d, J = 2.4 Hz, 1H), 8.85 (s, 1H), 8.63 (d, J = 5.3 Hz, 1H), 8.51 (dd, J = 8.8, 2.4 Hz, 1H), 8.26 (s, 1H), 8.19 (d, J = 8.8 Hz, 1H), 7.25 (d, J = 5.3 Hz, 1H), 4.48 (q, J = 7.0 Hz, 2H), 3.96 - 3.90 (m, 1H), 3.70 - 3.64 (m, 1H), 3.49 - 3.36 (m, 1H), 3.28 - 3.21 (m, 1H), 3.20 - 3.14 (m, 1H), 2.47 - 2.43 (m, 1H), 2.22 - 2.12 (m, 1H), 2.12 - 2.05 (m, 1H), 2.02 (s, 3H), 1.40 (t, J = 7.0 Hz, 3H), 1.09 - 1.03 (m, 2H), 0.90 - 0.83 (m, 2H). One proton obscured by DMSO peak.

[0212] [Table 9] TIFF0007595593000121.tif189170TIFF0007595593000122.tif208170TIFF0007595593 000123.tif206170TIFF0007595593000124.tif201170TIFF0007595593000125.tif59170

[0213] 4-(4-(cyclopropanesulfonamido)pyrimidin-2-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-1-methylpiperidine-4-carboxamide P319 [ka] To a solution of INTC247 (100 mg, 85 wt%, 1 equiv, 0.15 mmol) in DCM (2 mL) was added AcOH (82 mg, 78 μL, 9 equiv, 1.4 mmol) and formaldehyde (98 mg, 90 μL, 37 wt%, 8 equiv, 1.2 mmol) and the reaction mixture was stirred at room temperature for 30 min, after which sodium triacetoxyborohydride (3 equiv, 0.45 mmol) was added. The reaction mixture was stirred at room temperature for 20 h. The reaction mixture was concentrated in vacuo and the crude product was purified by chromatography on silica gel (80 g column, 10-50% MeOH / EtOAc) to give 4-(4-(cyclopropanesulfonamido)pyrimidin-2-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-1-methylpiperidine-4-carboxamide (65 mg, 0.12 mmol, 78%) as a white solid. Rt 0.86 min (UPLC, acidic); m / z 539 (M+H) + (ES + ); 1 H NMR (500 MHz, DMSO-d6) δ 9.91 (s, 1H), 9.01 (d, J = 2.4 Hz, 1H), 8.83 (s, 1H), 8.49 (dd, J = 8.8, 2.4 Hz, 1H), 8.24 (s, 1H), 8.16 (d, J = 8.8 Hz, 1H), 8.11 (s, 1H), 6.49 (s, 1H), 4.48 (q, J = 7.0 Hz, 2H), 3.30 (s, 3H), 3.20 - 3.15 (m, 3H), 2.82 (s, 2H), 2.70 - 2.61 (m, 3H), 2.38 - 2.35 (m, 1H), 1.40 (t, J = 7.0 Hz, 3H), 0.88 - 0.84 (m, 2H), 0.75 - 0.72 (m, 2H). One H is not observed.

[0214] Biological Examples Biological Example 1 – Inhibition of the Human CTPS1 Enzyme The enzyme inhibitory activity of the invented compounds against the target of interest was measured using the ADP-Glo™ Max assay (Promega, UK). The assay for human CTPS1 was performed in 50 mM Tris, 10 mM MgCl 2 , 0.01% Tween-20 and pH 8.0 accordingly. Finally, L-cysteine ​​was added to the above 1x assay buffer immediately before use to a final concentration of 2 mM. All reagents were from Sigma-Aldrich unless otherwise stated. Human full-length active C-terminal FLAG-His 8 -tag CTPS1 (UniProtKB - P17812, CTPS1[1-591]-GGDYKDDDDKGGHHHHHHH (CTPS1[1-591]-SEQ ID NO: 1)) was obtained from Proteros biostructures GmbH.

[0215] Assay Procedure 3x human CTPS1 protein was prepared in 1x assay buffer to the final working protein concentration required for the reaction. 2uL of 3x human CTPS1 protein per well was mixed with 2uL of 3x test compound per well (compound solutions were prepared in 1x assay buffer to the appropriate final 3x compound concentration depending on the concentration-response curve designed for the test compound) for 10 minutes at 25°C. The enzymatic reaction was initiated by adding a volume of 2uL per well of premixed substrate mix (UltraPure ATP (0.31mM), GTP (0.034mM), UTP (0.48mM), and L-glutamine (0.186mM) from the ADP-Glo™ Max kit), and the mixture was incubated at 25°C under sealed plate conditions with constant agitation at 500 revolutions per minute (rpm) for the appropriate length of time within the linear phase of the reaction measured. ADP-Glo™ Max reagent was added (6 μL / well) for 60 min, followed by ADP-Glo™ Max Development Reagent (12 μL / well) for 60 min, after which the signal was detected in a microplate reader (EnVision® Multilabel Reader, Perkin Elmer). Following addition of each reagent during the course of the assay, the assay plate was pulse centrifuged at 500 rpm for 30 s.

[0216] In all cases, the enzyme converts ATP to ADP, and the ADP-Glo™ Max Reagent then depletes any endogenous ATP remaining in the reaction. The ADP-Glo™ Max Detection Reagent converts the enzymatically produced ADP back to ATP and uses ATP as a substrate and luciferin as a substrate for the enzyme luciferase to generate light, which produces detectable fluorescence. The measured fluorescent signal is directly proportional to the amount of ADP produced by the enzymatic reaction, and a reduction in this signal by treatment with a compound demonstrates enzyme inhibition. The percent inhibition caused by each concentration of compound was calculated using the formula shown below.

number

[0217] Data for all compounds of formula (I) tested are presented below. [Table 10]

[0218] In this assay, all compounds of the present invention tested are found to show inhibition of CTPS1 enzyme.As a result, these compounds can be expected to be useful in inhibiting CTPS1.The compounds of the present invention are also expected to be useful as research tools, for example, for use in CTPS assay.

[0219] Biological Example 2 – RapidFire / MS-Based Enzyme Selectivity Assay Selectivity assessment of human CTPS1 versus CTPS2 by RapidFire / MS analysis The enzyme inhibitory activity of the compounds of the present invention against each isoform of interest can be measured using an optimized RapidFire high-throughput mass spectrometry (RF / MS) assay format. RF / MS assays for both human CTPS1 and CTPS2 were performed in 50 mM HEPES (Merck), 20 mM MgCl 2, 5 mM KCl, 1 mM DTT, 0.01% Tween-20, and can be carried out in an assay buffer of pH 8.0 accordingly. Human full length active C-terminal FLAG-His-tag CTPS1 (UniProtKB - P17812, CTPS1[1-591]-GGDYKDDDDKGGHHHHHHH (CTPS1[1-591]-SEQ ID NO: 1)) can be obtained from Proteros biostructures GmbH. Human full length active C-terminal FLAG-His-Avi tagged CTPS2 (UniProtKB - Q9NRF8, CTPS2 [1-586]-DYKDDDDKHHHHHGLNDIFEAQKIEWHE (human CTPS2 [1-586]-SEQ ID NO: 2)) can be obtained from Harker Bio.

[0220] Assay procedure Human CTPS (1 or 2) protein can be prepared in 1x assay buffer to the final working protein concentration required for the reaction. Using acoustic (ECHO) delivery, 2ul volumes of 2x CTPS (1 or 2) protein per well can be mixed with 40nL of compound and incubated at 25°C for 10 minutes. The enzymatic reaction of each isoform can then be initiated by adding 2uL per well of 2x substrate mixture in assay buffer. For hCTPS1: ATP (0.3mM), UTP (0.2mM), GTP (0.07mM), and L-glutamine (0.1mM). For hCTPS2: ATP (0.1mM), UTP (0.04mM), GTP (0.03mM), and L-glutamine (0.1mM). Each mixture can be incubated at 25°C for the appropriate length of time within the linear phase of the reaction as determined for each isoform. 60uL of stop solution (0.5uM 13 C 9 - 15 N 3 -CTP in 1% formic acid H 2200 solution) can be added and the plate can be immediately heat sealed and centrifuged at 4,000 rpm for 10 minutes. After centrifugation, the plate can be loaded onto an Agilent RapidFire microfluidic solid phase extraction system coupled to an API4000 triple quadrupole mass spectrometer (RF / MS) and analysis can be performed.

[0221] In all cases, the enzyme converts UTP to CTP. A highly specific and sensitive multiple reaction monitoring (MRM) MS method was used to measure the product of the enzymatic reaction, CTP, and a stable isotope-labeled standard of the product, CTP. 13 C 9 - 15 N 3 The readouts for data analysis can be optimized for the detection of the product CTP and the internal standard 13 C 9 - 15 N 3 -CTP: The ratio of the peak area to the peak area of ​​the 100% 150% CTP can be calculated. The following formula can be used for reporting the data:

number

[0222] For each screening plate, the mean values ​​of the negative (DMSO) and positive control values ​​were used to calculate the respective assay window (S / B) and Z' value. The median of the respective control values ​​was used to calculate the percent inhibition according to the following formula:

number

[0223] The percentage of inhibition was then plotted against compound concentration, and the 50% inhibitory concentration (IC 50 ) was determined from the resulting concentration-response curves.

[0224] The selectivity fold between CTPS1 and CTPS2 was then calculated using the following formula:

number

[0225] Certain compounds of formula (I) were tested in the above assay and data for all compounds tested are provided below. [Table 11]

[0226] All compounds tested in the assay described in Biological Example 2 were found to have at least 2-fold selectivity for CTPS1 over CTPS2, with many compounds having greater than 60-fold selectivity for CTPS1. In particular, these compounds may be expected to have utility in the treatment of diseases in which a selective CTPS1 inhibitory compound would be beneficial.

[0227] Throughout this specification and the appended claims, unless the context requires otherwise, the words "comprise" and variations such as "comprises" and "comprising" will be understood to mean the inclusion of a stated integer, step, group of integers or group of steps but not to the exclusion of any other integer, step, group of integers or group of steps.

[0228] The application of which this description and claims form part may be used as a basis for priority in respect of any subsequent application. The claims of such subsequent application may be directed to any feature or combination of features described herein. Such claims may take the form of product, composition, process, or use claims and may include, by way of example and without limitation, the following claims.

[0229] All publications cited in this specification, including, but not limited to, patents and patent applications, are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference as if set forth in full.

[0230] Cited References Evans, D. R. & Guy, H. I. Mammalian pyrimidine biosynthesis: fresh insights into an ancient pathway. J. Biol. Chem. 279, 33035-33038 (2004). Fairbanks, L. D. et al. Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors. J. Biol. Chem. 270, 29682-29689 (1995). Higgins, M. J. et al. Regulation of human cytidine triphosphate synthetase 1 by glycogen synthase kinase 3. J. Biol. Chem. 282, 29493-29503 (2007). Kursula, P. et al. Structure of the synthetase domain of human CTP synthetase, a target for anticancer therapy. Acta Crystallogr Sect F Struct Biol Cryst Commun. 62 (Pt7): 613-617 (2006). Lieberman I. Enzymatic amination of uridine triphosphate to cytidine triphosphate. The J. Biol. Chem. 222 (2): 765-75 (1956). Martin E. et al. CTP synthase 1 deficiency in humans reveals its central role in lymphocytes proliferation. Nature. Jun 12;510(7504):288-92 (2014). Erratum in: Nature. Jul 17;511(7509):370 (2014). McCluskey GD et al., Exploring the Potent Inhibition of CTP Synthase by Gemcitabine-5’-Triphosphate. Chembiochem. 17, 2240-2249 (2016). Ostrander, D. B. et al. Effect of CTP synthetase regulation by CTP on phospholipid synthesis in Saccharomyces cerevisiae. J. Biol. Chem. 273, 18992-19001 (1998). Sakamoto K. et al. Identification of cytidine-5-triphosphate synthase1-selective inhibitory peptide from random peptide library displayed on T7 phage. Peptides. 2017;94:56-63 (2017). Salu et al. Drug-eluting stents: a new treatment in the prevention of restenosis Part I: experimental studies. Acta Cardiol, 59, 51-61 (2004). Sousa J. E. et al. Drug-Eluting Stents. Circulation, 107 (2003) 2274 (Part I), 2283 (Part II). Tang R. et al. CTP synthase 1, a smooth muscle-sensitive therapeutic target for effective vascular repair. Arterioscler Thromb Vasc Biol. 33(10), 1-19, (2013). van den Berg, A. A. et al. Cytidine triphosphate (CTP) synthetase activity during cell cycle progression in normal and malignant T-lymphocytic cells. Eur. J. Cancer 31, 108-112 (1995). van Kuilenburg, A.B.P. et al. Identification of a cDNA encoding an isoform of human CTP synthetase. Biochimica et Biophysica Acta 1492548-552 (2000). The present application provides the following aspects of the invention. (Aspect 1) Formula (I): (chemical 1) TIFF0007595593000133.tif23170 A compound of the formula: During the ceremony, (a) A, V, W, X, Y, Z, R 1 、R 10 , and R 12 But below: (Case 2) TIFF0007595593000134.tif28170 If the above is true, then R 4 and R 5 is R 4 and R 5 together with the carbon atom to which it is attached, (C3) TIFF0007595593000135.tif38170 or (b) A, V, W, X, Y, Z, R 1 、R 10 , and R 12 But below: (C4) TIFF0007595593000136.tif29170 If the above is true, then R 4 and R 5 is R 4 and R 5 along with the carbon atom to which it is attached (C5) TIFF0007595593000137.tif24170 or (c) A, V, W, X, Y, Z, R 4 、R 5 、R 10 , and R 12 But below: (6) TIFF0007595593000138.tif27170 If the above is true, then R 1 teeth, (C7) TIFF0007595593000139.tif18170 or (d) A, V, W, X, Y, Z, R 4 、R 5 、R 10 , and R 12 But below: (8) TIFF0007595593000140.tif29170 If the above is true, then R 1 teeth, (9) TIFF0007595593000141.tif13170 or (e) A, X, Y, Z, R 1 、R 4 , and R 5 But below: (C10) TIFF0007595593000142.tif32170 If V, W, R 10 , and R 12 teeth, (Chem.11) TIFF0007595593000143.tif29170 or (f) A, V, W, R 1 、R 4 、R 5 、R 10 , and R 12 But below: (C12) TIFF0007595593000144.tif29170 Then Z, X, and Y are (C13) TIFF0007595593000145.tif16170 or (g) A, V, W, R 1 、R 4 、R 5 、R 10 , and R 12 But below: (C14) TIFF0007595593000146.tif26170 Then Z, X, and Y are (C15) TIFF0007595593000147.tif15170 or (h) A, V, W, R 1 、R 4 、R 5 、R 10 , and R 12 But below: (C16) TIFF0007595593000148.tif29170 Then Z, X, and Y are (C17) TIFF0007595593000149.tif16170 is The compound or a pharma- ceutically acceptable salt and / or solvate thereof. (Aspect 2) Formula (I): (C18) TIFF0007595593000150.tif21170 A compound of the formula: During the ceremony, (a) A, V, W, X, Y, Z, R 1 、R 10 , and R 12 But below: (C19) TIFF0007595593000151.tif24170 If the above is true, then R 4 and R 5 is R 4 and R 5 together with the carbon atom to which it is attached, (20) TIFF0007595593000152.tif34170 or (b) A, V, W, X, Y, Z, R 1 、R 10 , and R 12 But below: (21) TIFF0007595593000153.tif25170 If the above is true, then R 4 and R 5 is R 4 and R 5 along with the carbon atom to which it is attached (22) TIFF0007595593000154.tif20170 or (c) A, V, W, X, Y, Z, R 4 、R 5 、R 10 , and R 12 But below: (23) TIFF0007595593000155.tif26170 If the above is true, then R 1 teeth, (24) TIFF0007595593000156.tif18170 or (d) A, V, W, X, Y, Z, R 4 、R 5 、R 10 , and R 12 But below: (25) TIFF0007595593000157.tif27170 If the above is true, then R 1 teeth, (C26) TIFF0007595593000158.tif13170 or (e) A, X, Y, Z, R 1 、R4 , and R 5 But below: (27) TIFF0007595593000159.tif31170 If V, W, R 10 , and R 12 teeth, (28) TIFF0007595593000160.tif32170 or (f) A, V, W, R 1 、R 4 、R 5 、R 10 , and R 12 But below: (C29) TIFF0007595593000161.tif32170 Then Z, X, and Y are (30) TIFF0007595593000162.tif17170 or (g) A, V, W, R 1 、R 4 、R 5 、R 10 , and R 12 But below: (31) TIFF0007595593000163.tif27170 Then Z, X, and Y are (32) TIFF0007595593000164.tif16170 is The compound according to embodiment 1, which is the compound described above, or a pharma- ceutically acceptable salt and / or solvate thereof. (Aspect 3) N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxamide (33) TIFF0007595593000165.tif26170 or a pharma- ceutically acceptable salt and / or solvate thereof. (Aspect 4) 1-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)cyclohexane-1-carboxamide (34) TIFF0007595593000166.tif29170 or a pharma- ceutically acceptable salt and / or solvate thereof. (Aspect 5) N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-1-(2-(methylsulfonamido)pyrimidin-4-yl)cyclohexane-1-carboxamide (35) TIFF0007595593000167.tif28170 or a pharma- ceutically acceptable salt and / or solvate thereof. (Aspect 6) 1-(6-(cyclopropanesulfonamido)pyrazin-2-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)cyclohexane-1-carboxamide (36) TIFF0007595593000168.tif28170 or a pharma- ceutically acceptable salt and / or solvate thereof. (Aspect 7) 4-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)-N-(4-(6-ethoxypyrazin-2-yl)-2-methylphenyl)tetrahydro-2H-pyran-4-carboxamide (37) TIFF0007595593000169.tif27170 or a pharma- ceutically acceptable salt and / or solvate thereof. (Aspect 8) 1-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)cyclobutane-1-carboxamide (38) TIFF0007595593000170.tif23170 or a pharma- ceutically acceptable salt and / or solvate thereof. (Aspect 9) 4-(4-(cyclopropanesulfonamido)pyrimidin-2-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)tetrahydro-2H-pyran-4-carboxamide (39) TIFF0007595593000171.tif26170 or a pharma- ceutically acceptable salt and / or solvate thereof. (Aspect 10) 4-(2-(cyclopentanesulfonamido)pyrimidin-4-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)tetrahydro-2H-pyran-4-carboxamide (40) TIFF0007595593000172.tif26170 or a pharma- ceutically acceptable salt and / or solvate thereof.<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> (Aspect 11) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-((1-methylcyclopropane)-1-sulfonamido)pyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxamide <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> (C41) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> TIFF0007595593000173.tif25170<h2 style=";text-align:left;direction:ltr"> or a pharma- ceutically acceptable salt and / or solvate thereof. <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> (Aspect 12) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> 4-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-1-methylpiperidine-4-carboxamide <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> (C42) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> TIFF0007595593000174.tif32170<h2 style=";text-align:left;direction:ltr"> or a pharma- ceutically acceptable salt and / or solvate thereof. <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> (Aspect 13) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> 4-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-1-isopropylpiperidine-4-carboxamide <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> (C43) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> TIFF0007595593000175.tif34170<h2 style=";text-align:left;direction:ltr"> or a pharma- ceutically acceptable salt and / or solvate thereof. <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> (Aspect 14) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> 4-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)-N4-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-N1-isopropylpiperidine-1,4-dicarboxamide <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> (C44) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> TIFF0007595593000176.tif41170<h2 style=";text-align:left;direction:ltr"> or a pharma- ceutically acceptable salt and / or solvate thereof. <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> (Aspect 15) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> 4-(2-((1,1-dimethylethyl)sulfonamido)pyrimidin-4-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)tetrahydro-2H-pyran-4-carboxamide <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> (C45) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> TIFF0007595593000177.tif26170<h2 style=";text-align:left;direction:ltr"> or a pharma- ceutically acceptable salt and / or solvate thereof. <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> (Aspect 16) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> N-(4-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)tetrahydro-2H-pyran-4-yl)-5-(6-ethoxypyrazin-2-yl)picolinamide <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> (C46) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> TIFF0007595593000178.tif26170<h2 style=";text-align:left;direction:ltr"> or a pharma- ceutically acceptable salt and / or solvate thereof. <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> (Aspect 17) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> 1-Acetyl-4-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)piperidine-4-carboxamide <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> (C47) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> TIFF0007595593000179.tif31170<h2 style=";text-align:left;direction:ltr"> or a pharma- ceutically acceptable salt and / or solvate thereof. <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> (Aspect 18) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-((2-methylpropyl)sulfonamido)pyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxamide <h2 style=";text-align:left;direction:ltr"> (C48) TIFF0007595593000180.tif25170 or a pharma- ceutically acceptable salt and / or solvate thereof. (Aspect 19) 4-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)-N-(5-(6-cyclopropylpyrazin-2-yl)pyridin-2-yl)tetrahydro-2H-pyran-4-carboxamide (C49) TIFF0007595593000181.tif26170 or a pharma- ceutically acceptable salt and / or solvate thereof. (Aspect 20) N-(5'-chloro-[3,3'-bipyridin]-6-yl)-4-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxamide (50) TIFF0007595593000182.tif28170 or a pharma- ceutically acceptable salt and / or solvate thereof. (Aspect 21) N-(1-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)cyclopropyl)-5-(6-ethoxypyrazin-2-yl)picolinamide (51) TIFF0007595593000183.tif23170 or a pharma- ceutically acceptable salt and / or solvate thereof. (Aspect 22) 4-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)tetrahydro-2H-thiopyran-4-carboxamide 1,1-dioxide (52) TIFF0007595593000184.tif29170 or a pharma- ceutically acceptable salt and / or solvate thereof. (Aspect 23) N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(ethylsulfonamido)pyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxamide (53) TIFF0007595593000185.tif26170 or a pharma- ceutically acceptable salt and / or solvate thereof. (Aspect 24) 4-(2-(cyclopropylmethylsulfonamido) pyrimidin-4-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)tetrahydro-2H-pyran-4-carboxamide (54) TIFF0007595593000186.tif25170 or a pharma- ceutically acceptable salt and / or solvate thereof. (Aspect 25) 4-(4-(cyclopropanesulfonamido)pyrimidin-2-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-1-methylpiperidine-4-carboxamide (55) TIFF0007595593000187.tif29170 or a pharma- ceutically acceptable salt and / or solvate thereof.<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> (Aspect 26) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> The compound according to any one of embodiments 1 to 25, in the form of a pharma- ceutically acceptable salt. <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> (Aspect 27) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> The compound according to any one of embodiments 1 to 25, which is not in the form of a salt. <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> (Aspect 28) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> A compound according to any one of aspects 1 to 27 for use as a medicament. <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> (Aspect 29) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> 29. A compound according to embodiment 28 for use in reducing proliferation of T cells and / or B cells in a subject. <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> (Aspect 30) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> A compound according to aspect 28 for use in the treatment or prevention of inflammatory skin diseases such as psoriasis or lichen planus; acute and / or chronic GVHD such as steroid-resistant acute GVHD; acute lymphoproliferative syndrome (ALPS); systemic lupus erythematosus, lupus nephritis, or cutaneous lupus; transplantation; myasthenia gravis, multiple sclerosis or scleroderma / systemic sclerosis; cancer, such as blood cancer; or for use in improving recovery from vascular injury or vascular surgery and reducing morbidity and mortality associated with neointima and restenosis in a subject. <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> (Aspect 31) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> The blood cancer is acute myeloid leukemia, angioimmunoblastic T-cell lymphoma, B-cell acute lymphoblastic leukemia, Sweet's syndrome, T-cell non-Hodgkin's lymphoma (including natural killer cell / T-cell lymphoma, adult T-cell leukemia / lymphoma, enteropathic T-cell lymphoma, hepatosplenic T-cell lymphoma, and cutaneous T-cell lymphoma), T-cell acute lymphoblastic leukemia, B-cell non-Hodgkin's lymphoma (including Burkitt's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, 31. The compound of embodiment 30, wherein the compound is selected from the group consisting of myeloma, idiopathic lymphoma, myelodysplastic syndromes, myeloma, primary mediastinal large B-cell lymphoma, chronic myeloproliferative disorders (including chronic myelogenous leukemia, primary myelofibrosis, essential thrombocythemia, polycythemia vera), and chronic lymphocytic leukemia. <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> (Aspect 32) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> A pharmaceutical composition comprising a compound according to any one of aspects 1 to 27. <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> (Aspect 33) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> Formula (II): <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> (56) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> TIFF0007595593000188.tif23170<h2 style=";text-align:left;direction:ltr"> A compound of the formula: <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> In the formula, R is H, C <h2 style=";text-align:left;direction:ltr"> 1~4 <h2 style=";text-align:left;direction:ltr"> alkyl (e.g., methyl and ethyl), or benzyl; X, Y, Z, R <h2 style=";text-align:left;direction:ltr"> 1 <h2 style=";text-align:left;direction:ltr"> 、R <h2 style=";text-align:left;direction:ltr"> 4 <h2 style=";text-align:left;direction:ltr"> , and R <h2 style=";text-align:left;direction:ltr"> 5 <h2 style=";text-align:left;direction:ltr"> is as defined in aspect 1 <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> The compound or a salt thereof, such as a pharma- ceutically acceptable salt. <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> (Aspect 34) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> Formula (XXXIII): <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> (57) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> TIFF0007595593000189.tif23170<h2 style=";text-align:left;direction:ltr"> A compound of the formula: <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> In the formula, R is H, C <h2 style=";text-align:left;direction:ltr"> 1~4 <h2 style=";text-align:left;direction:ltr"> alkyl (e.g., methyl and ethyl), or benzyl; X, Y, Z, R <h2 style=";text-align:left;direction:ltr"> 1 <h2 style=";text-align:left;direction:ltr"> 、R <h2 style=";text-align:left;direction:ltr"> 4 <h2 style=";text-align:left;direction:ltr"> , and R <h2 style=";text-align:left;direction:ltr"> 5 <h2 style=";text-align:left;direction:ltr"> is as defined in aspect 1 <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> The compound or a salt thereof, such as a pharma- ceutically acceptable salt. <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> (Aspect 35) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> Formula (XXXIV): (58) TIFF0007595593000190.tif23170 A compound of the formula: In the formula, R is H, C 1~4 alkyl (e.g., methyl and ethyl), or benzyl; X, Y, Z, R 1 、R 4 , and R 5 is as defined in aspect 1 The compound or a salt thereof, such as a pharma- ceutically acceptable salt. (Aspect 36) Formula (XXXXII): (59) TIFF0007595593000191.tif26170 A compound of the formula: In the formula, R is H, C 1~4 alkyl (e.g., methyl and ethyl), or benzyl; X, Y, Z, R 1 、R 4 , and R 5 is as defined in aspect 1 The compound or a salt thereof, such as a pharma- ceutically acceptable salt. (Aspect 37) ·Formula (LXI): (60) TIFF0007595593000192.tif26170 Compounds of Formula (LXII): (61) TIFF0007595593000193.tif26170 Compounds of the formula: ·Formula (XXXI): (62) TIFF0007595593000194.tif32170 A compound of the formula: In the formula, W, V, Z, Y, X, R 1 、R 4 、R 5 、R 10 , and R<h2 style=";text-align:left;direction:ltr"> 12 <h2 style=";text-align:left;direction:ltr"> is as defined in aspect 1 <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> A compound selected from the group consisting of the above compounds, or a salt thereof, such as a pharma- ceutically acceptable salt. <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> (Aspect 38) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> Formula (XXXIVa): <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> (63) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> TIFF0007595593000195.tif21170<h2 style=";text-align:left;direction:ltr"> A compound of the formula: <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> In the formula, R is H, C <h2 style=";text-align:left;direction:ltr"> 1~4 <h2 style=";text-align:left;direction:ltr"> alkyl (e.g., methyl and ethyl), or benzyl; X, Y, Z, R <h2 style=";text-align:left;direction:ltr"> 4 <h2 style=";text-align:left;direction:ltr"> , and R <h2 style=";text-align:left;direction:ltr"> 5 <h2 style=";text-align:left;direction:ltr"> is as defined in aspect 1 <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> The compound or a salt thereof, such as a pharma- ceutically acceptable salt. <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> (Aspect 39) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> Formula (IP): <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> (64) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> TIFF0007595593000196.tif36170<h2 style=";text-align:left;direction:ltr"> A compound of the formula: <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> In the formula, P is a suitable nitrogen protecting group such as Boc, and W, V, Z, Y, X, R <h2 style=";text-align:left;direction:ltr"> 1 <h2 style=";text-align:left;direction:ltr"> 、R <h2 style=";text-align:left;direction:ltr"> 4 <h2 style=";text-align:left;direction:ltr"> 、R <h2 style=";text-align:left;direction:ltr"> 5 <h2 style=";text-align:left;direction:ltr"> 、R <h2 style=";text-align:left;direction:ltr"> 10 <h2 style=";text-align:left;direction:ltr"> , and R <h2 style=";text-align:left;direction:ltr"> 12 <h2 style=";text-align:left;direction:ltr"> is as defined in aspect 1 <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> The compound, and <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> Formula (I-DP): <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> (65) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> TIFF0007595593000197.tif34170<h2 style=";text-align:left;direction:ltr"> A compound of the formula: <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> In the formula, W, V, Z, Y, X, R <h2 style=";text-align:left;direction:ltr"> 1 <h2 style=";text-align:left;direction:ltr"> 、R <h2 style=";text-align:left;direction:ltr"> 4 <h2 style=";text-align:left;direction:ltr"> 、R <h2 style=";text-align:left;direction:ltr"> 5 <h2 style=";text-align:left;direction:ltr"> 、R <h2 style=";text-align:left;direction:ltr"> 10 <h2 style=";text-align:left;direction:ltr"> , and R <h2 style=";text-align:left;direction:ltr"> 12 <h2 style=";text-align:left;direction:ltr"> is as defined in aspect 1 <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> The compound <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> or a salt, such as a pharma- ceutically acceptable salt, thereof. <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> (Aspect 40) <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> Formula (II-a): (66) TIFF0007595593000198.tif28170 In the formula, R is H, C 1~4 alkyl (e.g., methyl and ethyl), or benzyl; X, Y, Z, and R 1 is as defined in aspect 1 compound, Formula (XXXIII-a): (67) TIFF0007595593000199.tif30170 In the formula, R is H, C 1~4 alkyl (e.g., methyl and ethyl), or benzyl, and X, Y, and Z are as defined in embodiment 1. compound, Formula (XXXIVa-a): (68) TIFF0007595593000200.tif30170 In the formula, R is H, C 1~4 alkyl (e.g., methyl and ethyl), or benzyl, and X, Y, and Z are as defined in embodiment 1. or a salt, such as a pharma- ceutically acceptable salt thereof. (Aspect 41) A compound selected from the group consisting of INTC180-INTC183, INTC185, INTC189, INTC193-INTC196, INTC200, INTC202, INTC204, INTC206, INTC209, INTC211, INTC213, INTC217, INTC219-INTC222, INTC241-INTC243, INTC246, and INTC247, or a salt thereof, such as a pharma- ceutically acceptable salt. (Aspect 42) A compound, compound for use, or composition according to any one of aspects 1 to 27, wherein said compound of formula (I) is in natural isotopic form.

Claims

1. N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(ethylsulfonamido)pyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxamide: [Formula 1] or a salt and / or solvate thereof.

2. The compound of claim 1, N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(ethylsulfonamido)pyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxamide: [chemical 2] or a pharma- ceutically acceptable salt and / or solvate thereof.

3. The compound according to claim 2, wherein N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(ethylsulfonamido)pyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxamide is [C3] Pharmaceutically acceptable salts and solvates of:

4. The compound according to claim 2, wherein N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(ethylsulfonamido)pyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxamide is [C4] A pharma- ceutically acceptable solvate of.

5. The compound according to claim 2, wherein N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(ethylsulfonamido)pyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxamide is [C5] A pharma- ceutically acceptable salt of

6. N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(ethylsulfonamido)pyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxamide: [C6] 2. The compound of claim 1,

7. A pharmaceutical composition comprising a compound according to any one of claims 2 to 6, or a pharma- ceutically acceptable salt and / or solvate thereof.

8. The pharmaceutical composition of claim 7 for use in reducing proliferation of T cells and / or B cells in a subject.

9. The pharmaceutical composition of claim 7 for use in the treatment or prevention of inflammatory skin diseases; acute and / or chronic GVHD; acute lymphoproliferative syndrome (ALPS); systemic lupus erythematosus, lupus nephritis, or cutaneous lupus; transplantation; myasthenia gravis, multiple sclerosis or scleroderma / systemic sclerosis; cancer in a subject; or for use in improving recovery from vascular injury or vascular surgery and reducing morbidity and mortality associated with neointima and restenosis in a subject.

10. 8. The pharmaceutical composition of claim 7 for use in the treatment of cancer.

11. The pharmaceutical composition of claim 10, wherein the cancer is a blood cancer.

12. 12. The pharmaceutical composition of claim 11, wherein the hematological cancer is selected from the group consisting of acute myeloid leukemia, angioimmunoblastic T-cell lymphoma, B-cell acute lymphoblastic leukemia, Sweet's syndrome, T-cell non-Hodgkin's lymphoma, T-cell acute lymphoblastic leukemia, B-cell non-Hodgkin's lymphoma, hairy cell leukemia, Hodgkin's lymphoma, lymphoblastic lymphoma, lymphoplasmacytic lymphoma, mucosa-associated lymphoid tissue lymphoma, multiple myeloma, myelodysplastic syndromes, plasma cell myeloma, primary mediastinal large B-cell lymphoma, chronic myeloproliferative disorders, and chronic lymphocytic leukemia.

13. The pharmaceutical composition of claim 10, wherein the cancer is a non-hematological cancer.

14. 14. The pharmaceutical composition of claim 13, wherein the non-hematological cancer is selected from the group consisting of bladder cancer, breast cancer, melanoma, neuroblastoma, malignant pleural mesothelioma, and sarcoma.

15. A pharmaceutical composition according to any one of claims 7 to 14 for use in a human subject.

16. A compound of formula (IIa): [C7] where R is H, C 1-4 alkyl, or benzyl. Or its salt.

17. N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylthio)pyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxamide (INTC182): [C8] or a salt thereof.

18. N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonyl)pyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxamide (INTC204): [C9] or a salt thereof.

19. The compound, salt, and / or solvate thereof according to any one of claims 1 to 6, which is in natural isotopic form.

Citation Information

Patent Citations

  • Methods and pharmaceutical compositions for inhibiting t-cell proliferation in a subject in need thereof (ctps1 inhibitors such as norleucine)

    JP2016523818A